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ABSTRACT 
 
 Neuroinflammation is a major driving force in the progression of 
neurodegenerative disorders.  Nicotinic acetylcholine receptors, as well as 
cannabinoid CB2 receptors, have been shown to have strong anti-inflammatory 
properties when activated.  These effects are shown, in vivo, to be a result of 
stimulation of α7 nAChRs and CB2 cannabinoid receptors.  Microglia cells, an 
immune cell in the brain, are shown to express both of these receptor subtypes.  
The studies detailed herein, investigated the ability of two compounds, nicotine 
and ∆9-THC, in modulation of inflammatory processes.  Stimulation of these 
receptors on microglia using nicotine and ∆9-THC blocked the activation of these 
cells, observed through reductions in pro-inflammatory cytokine production.  
Reductions in inflammation as well as pathology in the PSAPP mouse model of 
Alzheimer’s Disease were also observed following nicotine and ∆9-THC 
administration. These data raise the possibility that α7 nAChRs and CB2 
cannabinoid receptors may prove to be viable and effective strategy for reducing 
neuroinflammation observed in neurodegenerative disease.  
  
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Microglia and neuroinflammation 
 Microglia, the resident macrophages of the CNS, play important roles in 
immune regulation and neuronal homeostasis in the brain (Hanisch and 
Ketterman. 2007; Streit, 2005).  Microglia are established early in brain 
development and studies have indicated that perivascular microglia are 
monocytic in origin and may be used to replenish CNS populations throughout 
adult life.  They belong to a family of mononuclear phagocytic cells, but the 
presence of microglia in the fragile neuronal environment of the brain, and their 
distinct morphological features clearly sets them apart from other peripheral 
macrophages (Aloisi 2001).  Multiple lines of evidence suggest that microglia 
play a critical role in the etiology of various neurodegenerative diseases.  While 
an important role of microglial cells is to support and sustain proper neuronal 
function, under certain pathophysiological conditions, microglia can remain in an 
activated state for a prolonged period of time in which they secrete various 
inflammatory factors.  Chronically activated microglia are believed to cause and 
maintain an inflammatory response, and this inflammatory response can result in 
the neuronal cell loss that is observed in Alzheimer’s disease (AD) (El Khoury 
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and Luster, 2008), HIV-dementia (Yadav and Collman, 2009), Parkinson’s 
disease (Orr et al., 2002), amyotrophic lateral sclerosis (Sargsyan et al., 2005), 
and multiple sclerosis (Raivich and Banati, 2004).  Additionally this chronic 
activation can expose the CNS to high levels of a wide array of potentially 
neurotoxic molecules including pro-inflammatory cytokines, proteases, 
complement proteins, and reactive oxygen species (ROS).  There also exists an 
alternate view that suggest that dysregulation of microglial activation may prevent 
the appropriate immune responses necessary to respond to neuroinsults 
(Morgan et al., 2005)   
 In the healthy CNS, microglia are normally present in a resting or 
quiescent state and are characterized by having ramified processes and a small 
soma.  In this state microglia are actively and constantly surveying the immediate 
area with their long ramified protrusions.  They remain in this resting state 
receiving permanent tonic inhibitory signals from adjacent neurons, as the 
continually monitor the CNS environment.  The loss of this microglial-neuronal 
cross talk (Nelson et al., 2002), as well as other endogenous signals such as the 
presence of extracellular ATP (Streit 2000), can cause a rapid transformation of 
ramified microglia into an activated state and migration to sites of injury.  
Microglia may also undergo these morphological changes and become activated 
in response to exogenous signals from bacterial or viral infections in the CNS 
(Mariani and Kielian, 2009), and to direct physical CNS injury.  These changes 
include the shortening of cellular projections and enlargement of the soma 
resulting in an amoeboid phenotype.  These activated microglia can then migrate 
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to the site of injury and produce cytokines and chemokines, as well as a large 
number of cell surface activation antigens.  The activation of microglia is normally 
seen as a protective mechanism regulating tissue repair, but extended periods of 
microglial activation can result in neuronal dysfunction and cell death.   
Microglia, similarly to macrophages, can be divided into two polarized 
functional groups.  These groups are categorized as M1 or “classically activated” 
and M2 or “alternatively activated”.  In an M1 state microglia are known to 
produce high levels of pro-inflammatory cytokines, chemokines, and reactive 
oxygen species, which can result in damage to healthy tissue (Martinez et al., 
2008).  The M2 response is believed to be anti-inflammatory by suppressing 
destructive immune reactions and promoting tissue remodeling.  A recent study 
by S. Jimenez and colleagues (2008), was able to show the co-existence of the 
neurotoxic M1 microglia and the regenerative M2 microglia from a murine 
microglial cell line as well as primary cultured hippocampal microglia from a 
transgenic mouse model of AD.  Interestingly, they also found that this mouse 
model shows an age dependant shift from primarily an alternative M2 to a 
classical M1 activation.  Functional tests of microglia from normal mice, after 
CNS injury, initially show a transient anti-inflammatory M2 response that was 
quickly overtaken by the M1 neurotoxic response, indicating that this 
phenomenon may be common in other neurodegenerative disorders as well 
(Kigerl et al., 2009). 
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1.1.1 The CD40 receptor and microglia 
CD40 is a type I transmembrane protein; the mature molecule is 
composed of 277 amino acids with a 193-amino-acid extracellular domain, 
including a 21-amino-acid leader sequence, a 22-amino-acid transmembrane 
domain and a 62-amino-acid intracellular tail (GenBank No. X60592; 3).  CD40 
may also be found as a heteromultimeric complex on the cell surface (Tan et al., 
2002a). CD40 belongs to the tumor necrosis factor receptor (TNF)/nerve growth 
factor (NGF) receptor super-family, other members of which include TNF-RI, 
TNF-RII, and the low affinity NGF receptor p75 NTR (van Kooten et al., 2000a).  
The amino acid backbone of CD40 predicts a protein of 29 kDa, although it is 
typically found to be between 45 and 50 kDa depending on the cell type, 
indicating post-translational modification (for instance, N-linked glycosylation at 
position Asn240 in human CD40, which is conserved in mouse, human and 
cattle) (van Kooten et al., 2000b). In addition to its transmembrane form, CD40 
may be secreted as a smaller type II isoform (typically 18 kDa). This secretory 
form is generated by alternate mRNA splicing, such that the transmembrane 
domain and cytoplasmic regions are not translated (Tone et al., 2001). 
Most of our knowledge about CD40 comes from peripheral immunity, an 
area of study that has witnessed rapid expansion over the past 5 years.  A 
variety of professional and non-professional antigen-presenting cells (APCs) 
express CD40, including dendritic cells, B cells, monocytes and tissue 
macrophages.  Its cognate ligand, CD40 ligand (CD40L), is typically found on the 
surface of T lymphocytes, although CD40L can also be secreted as a smaller 
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soluble protein.  Broadly, the CD40–CD40L interaction is an accessory co-
stimulatory pathway that plays major roles in at least four key immune cell 
processes: activation, maturation/differentiation, growth/proliferation, and 
regulation of apoptosis.  Regarding immune cell activation, it is currently thought 
that the interaction of APC CD40 with T helper (Th) cell CD40L primes the APC, 
which in turn activates the cytotoxic T lymphocyte function in CD8+ T cells, 
resulting in eradication of tumors and viral infection (Clarke, 2000).  A role of the 
CD40–CD40L interaction in so-called Th cell immune deviation from a Th2 to a 
Th1 immunotype has also been reported (Martin et al., 2010), resulting in a 
boosted cellular immune response essential for combating primary infection. 
Interaction of CD40L on the surface of activated T cells with B cell CD40 acts as 
an accessory signal to promote B-cell proliferation and differentiation into 
antibody-secreting plasma cells, initiates the IgM to IgG antibody isotype switch, 
and opposes B-cell apoptosis (Jelinek, 2000; Kishimoto et al., 2000).  Thus, the 
CD40–CD40L interaction is also an important regulator of the humoral (antibody) 
immune response essential for protection from re-infection.  Effects of CD40 
ligation on maturation, activation, and survival of dendritic cells, professional 
APCs essential for mounting an antigen-specific immune response, have also 
been reported (McLellan et al., 2000; Kikuchi et al., 2000).  Thus, irrespective of 
the peripheral immune cell under consideration, the CD40–CD40L interaction is 
generally trophic, resulting in increased cellular and humoral peripheral immunity. 
 Studies have identified functional CD40 on the surface of a number of 
CNS cells, suggesting that CD40 plays a much broader role in cellular processes 
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than once suspected.  CD40 expression has been identified in vitro on vascular 
endothelial and smooth muscle cells, important constituents of the blood–brain 
barrier (BBB).  Interestingly, these cells have additionally been found to express 
CD40L (Mach et al., 1997).  While constitutive CD40 expression is generally low 
on these cells, stimulation with the pro-inflammatory cytokines interleukin-1β (IL-
1β) or interferon-γ (IFN-γ) results in marked enhancement of CD40 expression 
(Mach et al., 1997; Tan et al., 1999a), suggesting a role of CD40 in 
neuroinflammation.   
 Like astroglia, smooth muscle, and endothelial cells; microglia 
constitutively express relatively low levels of CD40 (<5% by fluorescence 
activated cell sorter analysis, Tan et al., 1999b; Aloisi et al., 1999).  However, 
when microglia are stimulated with the pro-inflammatory cytokine IFN-γ (between 
1 and 10 U/ml), these expression levels are dose-dependently enhanced by as 
much as 20-fold (Tan et al., 1999b, Nguyen and Benveniste, 2000a; Aloisi et al., 
2000).  Additionally, stimulation of microglia with the acute-phase pro-
inflammatory cytokine TNF-α also promotes CD40 expression, albeit at more 
modest levels than IFN-γ. Subsequent ligation of microglial CD40, by CD40L, 
leads to marked production of tumor necrosis factor-α (TNF-α), which has been 
found to mediate neuronal injury in vitro (Tan et al., 1999b), suggesting that 
CD40 on microglia may play a role in potentially pathogenic neuroinflammatory 
processes.   
 Studies have investigated the direct inhibition of CD40–CD40L interaction 
by using a neutralizing antibody to CD40L.  Lessons from animal models of 
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neuroinflammatory diseases shed light on the possible modes of action of CD40–
CD40L interruption via antibody.  One suggested mode of action of CD40–
CD40L blockade in the experimental allergic encephalitis (EAE) mouse model is 
interruption of Th1 cell differentiation and function (Howard et al., 2003).  The 
relevance of peripheral Th1/Th2 mechanisms to other disorders is well known, 
but is just recently being considered in neuroinflammatory disorders such as 
Alzheimer’s disease.   
 
1.1.2 CD45 and microglial activation 
CD45 is a membrane-bound protein-tyrosine phosphatase (PTPase), 
which is expressed on all nucleated hematopoietic cells, including T and B 
lymphocytes, where it has been shown to play a critical role in negative 
regulation of cellular activation (Tan et al., 2000a). It modulates signaling through 
cytokine receptors as well as cellular adhesion (Irie-Sasaki et al., 2001, Sasaki et 
al., 2001).  In addition, CD45 is expressed on microglia at low to moderate levels, 
and is markedly increased following activation of these cells (Townsend et al., 
2004b). The CD45 protein is encoded by a single gene (PTPRC; protein tyrosine 
phosphatase, receptor-type C) and different isoforms can be created by 
alternative splicing of three variable exons 4, 5, and 6 (also known as A, B, or C) 
that encode part of the extracellular region of the molecule (Townsend et al., 
2004b).  However, the functional roles of each of the CD45 isoforms on T-cells 
as well as other nucleated hemopoietic cells remains unclear.  It is generally 
thought that CD45 couples to Src family kinases, functioning to maintain Src in a 
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dephosphorylated, and hence inactive, state (Tan et al., 2000a). This is 
supported by studies in T and B lymphocytes, where CD45-deficient cell lines 
demonstrate increased Src activity (Penninger et al., 2001). Yet, the mechanism 
of CD45 modulation of Src activity is complex, and it is thought that CD45 might 
function as both a positive and negative regulator of Src in a site-specific manner 
(Thomas and Brown 1999).  Other studies indicate that CD45 can also function 
as a Janus Kinase PTPase that negatively controls cytokine-receptor signaling.   
Similar to other cells of hemopoietic lineage, resting microglia have been 
shown to express CD45 at low to moderate levels, and CD45 expression 
markedly increases following activation.  Microglia, in vitro, have been shown to 
express several isoforms of CD45 that are identified as CD45RA, CD45RB, and 
CD45RC.  Also studies have shown that the most predominant isoform 
expressed upon activation of these cells is CD45RB (Townsend et al., 2004b).  In 
addition, it has been demonstrated that microglia located in the frontal cortex and 
hippocampus of normal aging individuals express CD45 and this expression level 
is markedly increased in Alzheimer’s disease (AD) patients (Ho et al., 2005). 
Furthermore, in an animal model of neurodegeneration, upregulation of PTP 
signaling in activated microglia was found in and around degenerating brain 
regions (Penninger et al., 2001).  Although endogenous ligands have yet to be 
identified, studies have shown that cross-linking CD45 with an anti- CD45 
antibody resulted in activation of this receptor.  Co-treatment of microglia with 
CD40L and agonistic anti-CD45 antibody results in significant inhibition of 
microglial TNF-α production via inhibiting p44/42 mitogen activated protein 
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kinase (MAPK) activity, a downstream signaling event resulting from Src-family 
kinase activation (Tan et al., 2000a).  The various isoforms of CD45 can be 
individually activated with isoform specific agonistic anti-CD45 antibodies.  For 
example, activation of the CD45RB isoform with an isoform specific antibody is 
able to potently oppose LPS-induced microglial activation in vitro.  Also 
administration, in vivo, of an agonistic anti-CD45RB antibody is able to attenuate 
CNS inflammation induced by intraperitoneal injection with LPS (Townsend et al., 
2004b).  These findings suggest that tailored stimulation of the CD45 signaling 
pathway may be directly applicable to suppression of microgliosis associated 
with neuroinflammatory disorders.  
Since the expression levels of CD45 on quiescent microglia is found to be 
low, and on activated cells expression is markedly increased, CD45 has shown 
to be a marker that can be used to identify the state of microglia in 
neuroinflammatory diseases.  This phenomenon of CD45 expression has been 
observed in cases of AD (Townsend et al., 2004) and multiple sclerosis (MS) 
(Olson 2010), and may become a useful tool in the regulation of inflammation in 
these disorders. 
 
1.2 Neurodegenerative disease 
 The population of the United States is aging, and an increasing number of 
people are becoming afflicted with neurodegenerative diseases.  
Neurodegenerative diseases are the result of gradual and progressive loss of 
neuronal cells, which eventually leads to central nervous system (CNS) 
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dysfunction.  A central step in the disease processes is the activation of the brain 
mononuclear phagocytic cells, called microglia.  Microglia represent a major 
cellular component of the brain, where they constitute a widely distributed 
network of immunoprotective cells.  Activation of microglia in the area of 
degenerating neuronal cells has been identified in a broad range of 
neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s 
disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and 
Huntington’s chorea (HD) (Eikelenboom et al. 2002).  This activation has been 
proposed to contribute to neuronal dysfunction and neuronal cell death that is 
seen in AD.  This is partly due to the cytokines, chemokines, and other 
inflammatory mediators that are produced, by microglia, in response to 
exogenous or endogenous stimuli.  Great progress has been made over the last 
several decades in respect to the causes of most neurodegenerative disease.  
The discovery of heritable genetic factors and mutations for each respective 
disease has given great insight into the etiology and progression of these 
disease states.   
 
1.2.1 Alzheimer’s disease 
 First described by Alois Alzheimer in 1906, Alzheimer’s disease is 
currently the most common form of dementia.  AD is an age related progressive 
neurodegenerative disorder associated with cognitive decline and profound 
neuronal loss.  It that can be distinguished from other types of dementia due to 
two specific pathological hallmarks found in the brain; amyloid plaques 
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composed of the Aβ peptide and neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated tau.  These pathologies can cause neuroinflammation, 
excitotoxicity, and oxidative stress which can eventually evoke neuronal cell 
death, as well as impair inter-neuronal communication.   
 Alzheimer’s disease is characterized by the accumulation of the Aβ 
peptide, a product from the cleavage of amyloid precursor protein (APP) by 
specific secretase enzyme complexes.  The proteolytic cleavage of membrane 
spanning APP into Aβ begins with the action of β-secretase (BACE) which 
results in the production of β-CTF, the Aβ-containing c-terminal fragment (Yan et 
al., 1999; Sinha and Leibeburg, 1999).  Subsequently, β-CTF is cleaved by a γ-
secretase complex composed of several proteins.  This results in the production 
of the Aβ peptide and the smaller γ-CTF protein (DeStooper et al., 1998; Sterner 
et al., 1999). 
 AD can be separated into two subcategories, in regards to genetic 
predisposition and approximate age of disease onset.  These categories include 
familial or early onset AD (FAD) and sporadic or late onset AD (SAD) with an age 
cutoff of 60-65 years old.  Only about 5% of AD cases are FAD resulting heritable 
genetic factors, with the remaining 95% SAD resulting from natural aging or 
some other CNS insult (Rocchi et al., 2003).  Current prescribed treatment for AD 
involves the use of donepezil, an acetylcholine esterase blocker, and memantine, 
a NMDA receptor blocker to help alleviate observed symptoms.  Although 
symptoms may initially improve or become stable the patient will eventually 
continue to decline as the medication becomes ineffective. 
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 Current evidence suggests that microglial activation is involved in the 
neuro-inflammatory component of many neurodegenerative diseases.  For 
example, in Alzheimer’s disease (AD) brain, reactive microglia are typically found 
in close proximity to senile plaques, and it has been suggested that they drive AD 
pathogenesis by exacerbating β-amyloid pathology (Wegiel et al., 2000). 
Following chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), AD 
patients demonstrate reduction in reactive microglia (but not other AD 
pathologies such as mean numbers of senile plaques, senile plaque subtypes, or 
neurofibrillary pathology) compared to non-users, suggesting that the mechanism 
underlying NSAID prophylaxis for AD is suppression of microglial activation 
(Mackenzie, 2000).   
Currently, approximately 10% of people in the U.S. that are over the age 
of 65, and 50% aged 85 and older have been diagnosed with AD.  This 
corresponds to over 5.2 million Americans that suffer from this disorder, and it is 
projected to increase to more then 13.2 million by 2050 (Herbert et al., 2003; 
Plassman et al., 2007).  World wide there were an estimated 30 million affected 
individuals in 2000, with a projected increase to over 85 million as current 
population ages.  The direct and indirect costs to treat this disease is 
approximately $94 billion in the US, and approximately $315.4 billion world wide.  
According to the Alzheimer’s Association Facts and Fiqures report (2009) AD has 
become the sixth-leading cause of death in the United States and the third most 
expensive disease to treat nationally.   
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1.3 Tobacco and cannabis use  
 According to the Centers for Disease Control and Prevention (CDC) 
tobacco smoking rates in the U.S. have stayed roughly the same over the last 5 
years.  There are an estimated 48 million, or approximately 21 percent of U.S. 
adults currently smoking tobacco based products.  These rates were found to not 
vary much based on age, but were higher among males.  Many tobacco smokers 
also use Marijuana, a common form of dried cannabis.  Marijuana is currently the 
most widely used illicit drug in the United States.  According to the latest data 
from the 2008 National Survey on Drug Use and Health, approximately 15.2 
million Americans reported marijuana use in the past month and with more than 
half of young adults aged 17-25 reported using the drug within the same time 
period.   
 Another phenomenon that public health researchers in the U.S. are 
becoming more aware of is “blunting”, or the use of hollowed out cigars as 
containers for marijuana (Soldz et al., 2003; Everett et al., 2000).  A “blunt” is a 
generic term that describes cigars that are approximately 2/3 of an inch in 
diameter and five inches long.  Their popularity is due to the ease of using cigar 
wrappers to roll up marijuana, and the fact that the wrappers are made from 
tobacco, a natural compound (Stoltz and Sanders, 2000).  This combination of 
tobacco and marijuana ultimately results in the intake of both nicotine and ∆9-
THC at the same time. 
 Both endogenous cholinergic and cannabinoid systems are crucial 
modulatory pathways in the CNS (Klein et al., 2003; Cobb and Davies, 2005).  
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The administration of ∆9-THC or nicotine in rodents produced multiple common 
responses including modulation of immune function, antinociception, and 
hypothermia (Onaivi, 2009).  The specific biochemical responses due to the 
interaction of nicotine and ∆9-THC are poorly understood in animal models 
despite the high rate of association of these two compounds in humans. 
 
1.4 Nicotinic acetylcholine receptors 
 Nicotinic acetylcholine receptors (nAChRs) are present in many of the 
bodies tissues and are currently the most widely investigated class of ionotropic 
receptors.  There are at least 17 different nAChR subunits currently identified, 
with the majority being of neuronal type (α2-10 and β2-4) and the remainder 
originating from muscle (α1, β1, δ, γ, and ε) (Lukas et al., 1999).  The channels 
formed by neuronal nAChR subunits can either be homomeric, where five 
identical subunits comprise the receptor, or heteromeric, where the pentameric 
channel is made from two or more different subunits.   
 Over the past several years there has been a rapid accumulation of data 
that suggests that nAChRs might play crucial roles in neurodegenerative 
diseases (O’Neill et al., 2002).  In many neurodegenerative disorders, including 
AD, it has been documented that there is a significant loss of nAChRs observed 
in post-mortem brain tissue (Burghaus et al., 2000).  This reduction is contrasted 
by the higher density of nAChR’s that are reported to be present in the brain of 
normal smokers (Perry et al., 1999).  More importantly, epidemiologic studies 
have indicated a consistent inverse relationship between nicotine intake and the 
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occurrence of PD, suggesting that smoking may be neuroprotective (Morens et 
al., 1995; Brenner et al., 1993).   
 
1.4.1 The α7 nAChR 
 The α7 nAChR is a homomeric ionotropic receptor that is composed 
entirely of five α7 nAChR subunits (Drisdel and Green, 2000).  These subunits 
are arranged spanning the cytoplasmic membrane to create a pore that is 
selectively permeable to calcium ions.  When the ligand, acetylcholine or 
nicotine, binds to the external surface of the receptor it causes a shift in the 
subunit configuration and allows calcium ions to enter the cell (Berg and Conroy, 
2002).  Like many other nAChRs, the α7 receptors are rapidly activated by an 
agonist then inactivated, closed, and then reset for subsequent activation.  α7 
nAChRs are especially sensitive to α-bungarotoxin, which is present in the 
venom of bungarus snake species (Arias, 2000).  This toxin irreversible and 
competitively binds to these receptors and blocks the opening of the channel.   
 Studies of α7 in the periphery have indicated that monocytes and 
macrophages express this receptor, and that it plays an important role in the 
cholinergic anti-inflammatory pathway.  Stimulation with an agonist leads to 
efficient suppression of cell activation and pro-inflammatory cytokines, such as 
TNF-α and IL-1β (Dong-Jie et al., 2009).  Recent publications have also been 
able to show that stimulation of the α7 cholinergic receptor markedly reduced the 
severity of acute (Giebelen et al., 2007), as well as chronic inflammation (Stix, 
2007).   
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Studies have shown that the α7 nAChR plays an important role in 
neuroprotection against various insults which could result in microglial activation 
and neuronal cell death (Lloyd and Williams, 2000; O’Neill et al., 2002).  
Stimulation of these receptors on glial cells (microglia and astrocytes) results in 
the reduction of pro-inflammatory cytokine expression and reactive oxygen 
species production.  α7 nAChRs are widely expressed in the brain, and have 
been observed in areas such as the CA1 region of the hippocampus, the 
entorhinal cortex, areas of the basal ganglia and the cerebellum.  Studies have 
also shown that there is a decline in nicotinic receptors, specifically α7 nAChRs, 
in these areas in response to aging and age related neurodegenerative diseases, 
possibly due to the loss of neuronal and glial pools of this nicotinic receptor (de 
Jonge and Ulloa, 2007).  This decrease in receptor density may result in an 
increase in microglial activation and subsequent neuroinflammation. 
 
1.5 Cannabinoid receptors 
 Until approximately 22 years ago, receptors for ∆9-THC were entirely 
unknown.  Some believed that its mechanism of action was by altering cellular 
membrane properties due to its high lipophilic nature.  In the early 1990’s, 
knowledge began to change with the discovery of the first receptor for ∆9-THC, 
the CB1 cannabinoid receptor (de Fonseca and Schneider, 2008).  This receptor 
was found to belong to the metabotropic G protein-coupled (GCPR) family of cell 
surface receptors.  Subsequently, the discovery of endogenous ligands 
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(endocannabinoids), and an additional receptor have dramatically increased the 
understanding in the field of cannabinergic research.   
 Currently there are two GPCRs that are firmly established as the targets 
for ∆9-THC and other cannabinoids.  These receptors are denoted as CB1 and 
CB2, and there is a 45% homology in amino acid composition between the two 
subsets (Felder and Glass, 1998).  Further investigation has shown that they are 
typical Gαi/o protein-coupled receptors which are pertussis toxin sensitive and 
their activation results in inhibition of adenylate cyclase (Howlett, 2002).  CB1 
receptors have been found to mediate many of the psychoactive effects of 
cannabinoids, while the CB2 subtype is principally believed to have anti-
inflammatory and immunosuppressive effects.   
 The discovery of the cannabinoid receptors has allowed for the 
identification of several compounds as endogenous ligands.  These compounds 
are commonly known as Anandamide and 2-Arachidonoylglycerol (2-AG).  They 
are both synthesized from the omega 6 fatty acid, arachidonic acid.  Also, due to 
their lipophilic nature are believed to be synthesized on demand, not stored in 
vesicles for later release (Felder and Glass, 1998).  Anandamide has be found to 
work effectively at both CB1 and CB2 receptors, while 2-AG is a full agonist at 
CB1 receptors and is a weak agonist at CB2 (Szabo et al., 2006).  There are also 
a large number of exogenous ligands such as ∆9-THC and Cannabidiol from 
Cannabis sativa as well as many more that have been synthesized in the 
laboratory.   
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1.5.1 The CB2 receptor 
 Marijuana and its active constituent, ∆9-THC, have been shown to 
suppress cell-mediated immune responses.  Many of these effects are mediated 
by the CB2 subclass of cannabinoid receptors (Klein et al., 2003).  These CB2 
receptors are not as widely expressed as their CB1 relative (Onaivi et al., 2006).  
Studies have identified it primarily in immune related organs such as the tonsils, 
spleen, thymus, and bone marrow (Whiteside et al., 2007).  The expression of 
CB2 receptors on specific cell types includes B lymphocytes, 
monocytes/macrophage, mast cells (Klein et al., 2003), and most recently 
microglial cells (Nunez et al., 2004). 
 Studies of CB2 stimulation on peripheral macrophages has shown reduced 
pro-inflammatory cytokine expression, as well at reductions in reactive oxygen 
species production (Hao et al., 2010).  Publications have also shown that CB2 
activation may prove to be a viable therapy for atherosclerosis, and other 
vascular disorders (Netherland et al., 2010).  This is primarily due to the resultant 
anti-inflammatory effects that are seen after stimulation of this receptor with an 
agonist. 
 Recently, there have been extensive studies of CB2 receptors on glial cells 
within the CNS.  These receptors have not only been implicated to control neural 
survival (Fernandez-Ruiz et al. 2007) but also mediate neuroprotection through 
anti-inflammatory actions (Facchinetti et al. 2003).  Stimulation of CB2 receptors 
found on glia prevents activation of these cells by both exogenous and 
endogenous stimuli.   
  
 
CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Cell Culture  
 
2.1.1 Immortalized murine N9 cell line 
 Murine N9 microglial cell lines, generated from myc-immortalized mice, 
were a kind gift from Dr. P. Ricciardi-Castagnoli (Universita Delgi Studi di Milano-
Bicocca, Milan, Italy).  N9 microglial cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 5% fetal bovine serum (FBS) and 
2mM glutamine.  During treatments all cultures were incubated at 37ºC with 10% 
CO2 in serum free medium.   
 
2.1.2 Murine microglial primary cell culture  
Murine primary culture microglial cells were isolated from mouse cerebral 
cortices and grown in (RPMI) 1640 medium supplemented with 5% fetal calf 
serum (FCS), 2 mM glutamine, 100 U/ml penicillin, 0.1 μg/ml streptomycin, and 
0.05 mM 2-mercaptoethanol (complete medium) according to previously 
described methods [27].  In short, cerebral cortices from newborn mice (1–2 day-
old) were isolated under sterile conditions and kept at 4°C. Isolated cortices were 
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then incubated in 0.25% trypsin for 5 – 15 minutes at 37˚C before mechanical 
dissociation of cells.  Cells were plated in 75-cm2 flasks and complete medium 
was added.  Primary cultures were kept for 14 days so that only glial cells 
remained and microglial cells were isolated by shaking flasks at 200 rpm on a 
Laboratory-Line™  incubator-shaker.  More than 98% of these glial cells stained 
positive for microglial marker membrane attack complex-1, Mac-1 (CD11b/CD18; 
Boehringer Mannheim, Indianapolis, IN; data not shown).  Additionally, between 
85 and 95% of microglial cells stained positive for CD45 (FITC-anti-CD45 
antibody was obtained from Pharmingen, San Diego, CA, USA) by fluorescence-
activated cell sorter (FACS) analysis as described previously (Tan et al. 1999a). 
Following isolation, primary microglia were seeded in 24-well poly-D-lysine 
coated culture plates at  a concentration of approximately 2 x 105 cells per well.  
All cultures were incubated in their complete medium at 37°C with 10% CO2 
during all treatments.  All animal protocols were approved by the Committee of 
Animal Research at the University of South Florida, in accordance with 
guidelines from the National Institutes of Health.  
 
2.2 Animals – Mice 
 
2.2.1 Animals and microglial cell cultures 
Breeding pairs of C57Bl/6 mice were purchased from Jackson Laboratory 
(Bar Harbor, ME, USA) and housed in the animal facility at the University of 
South Florida, College of Medicine. PSAPP mice of a hybrid B6/SJL background 
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(line 2576; Hsiao et al., 1996) were purchased from Taconic (Germantown, NY, 
USA).   
 
2.2.2 Housing and maintenance 
  All animals were given ad libitum access to water and chow and 
maintained on a 12 hour light/dark cycle.  All animals were housed in the College 
of Medicine Animal Facility at the University of South Florida (USF) and all 
experiments were performed in compliance with protocols approved by the USF 
Institutional Animal Care and Use Committee (IACUC).   
 
2.2.3 Intraperitoneal injection (i.p.) 
 Mice were scruffed gently to immobilized the head and prevent any undue 
stress to the animal.  Intraperitoneal injections of therapeutic agents were given 
on the right side of the abdomen using a sterile 1ml syringe with a short 26 
gauge needle. 
 
2.2.4 Tissue isolation and preparation 
 Mice were anesthetized with isofluorane and transcardially perfused with 
ice-cold physiological phosphate buffered saline (PBS) containing heparin (10 
U/mL).  Brains were rapidly isolated and halved sagitally using a mouse brain 
slicer (Muromachi Kikai, Tokyo, Japan).  Left hemispheres were homogenized for 
western blot and ELISA analysis.  Briefly, brains were homogenized in ice-cold 
lysis buffer by sonication for 3 minutes.  The resulting homogenates were 
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allowed to stand for 15 minutes at 4°C and were subsequently centrifuged at 
14,000 g for 15 minutes at 4°C.  Protein levels in cell lysate supernatants were 
determined and normalized by BCA assay in accordance with the manufacturer’s 
instructions.  The right hemispheres  were used for or cryostat sectioning.  
Briefly, brains were fixed in 4% paraformaldehyde in PBS at 4°C overnight and 
routinely processed in sucrose gradients before being encased in tissue freezing 
medium.  Following embedment, twenty four coronal sections from each brain 
(25µm thickness) were cut with a 50 µm interval. 
 
2.3 Reverse transcription PCR and small interfering RNA 
 
2.3.1 Alpha 7 nAChR 
 Total RNA was isolated from primary cultured microglial cells using a 
single extraction method (TRIZOL reagent, Gibco-BRL, Grand Island, NY, USA) 
and cDNA was synthesized using a cDNA cycle kit (Invitrogen, Carlsbad, CA, 
USA) as previously described (Tan et al. 1999a). PCR was performed for 30 
cycles, with each cycle consisting of 94°C for 1 min, 55°C for 2 min, and 72°C for 
2 min, followed by a final extension step at 72°C for 10 min. PCR products were 
resolved on 1.2% ethidium bromide-stained agarose gels, and visualized by 
ultraviolet transillumination. 
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2.3.2 CB2 cannabinoid receptors 
 Total RNA was isolated from primary cultured microglial cells using Trizol 
reagent Invitrogen, Carlsbad, CA) as recommended in the manufacturer's 
protocol. RNA concentration was measured by spectrophotometry at 260 nm. 
RT-PCR was performed.  Briefly, cDNA was prepared by mixing 1 μg of total 
RNA from each treatment with an oligo (dT) primer and the MMLV reverse 
transcriptase (Invitrogen); the reaction mixture was incubated in a 37°C water-
bath for 50 min before heat inactivation of the mixture by increasing the 
temperature to 70°C for 10 min.  This cDNA reaction mixture (20 μl) was diluted 
with 180 μl of DNase/RNase-free water and 10μL of the cDNA solution was used 
for gene specific PCR.  Samples not undergoing reverse transcription were run in 
parallel to control for technical errors leading to DNA contamination (data not 
shown).  Mouse β-actin was amplified from all samples as a housekeeping gene 
to normalize expression.  PCR was performed with each cycle consisting of 94°C 
for 1 min, 55°C for 2 min, and 72°C for 2 min, followed by a final extension step 
at 72°C for 10 min.  PCR products were resolved on 1.2% ethidium bromide-
stained agarose gels, and visualized by ultraviolet transillumination.  
 
2.3.3 CB2 small interfering RNA 
N9 cells were transfected with specific murine CB2 targeting siRNA 
designed to knockdown murine CB2 expression (Humesis Biotechnology 
Corporation, New Orleans, LA, USA).  Briefly, N9 cells were seeded in 24-well 
plates and cultured until they reached 70% confluency. The cells were then 
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transfected with 100 nM anti-CB2 siRNA or anti-green fluorescent protein (GFP; 
non-targeting control; Humesis) using Code-Breaker transfection reagent 
(Promega, Madison, WI, USA) and cultured for an additional 18 hr in serum-free 
MEM. The cells were allowed to recover for 24 hr in complete medium (MEM 
10% FBS) before treatments. The cells were evaluated by Western 
immunodetection for the expression of CB2 using anti-CB2 antibodies (Santa 
Cruz) following siRNA treatment.  Cells were also cultured for 4 hr with LPS, 
JWH-015, or various combinations, and TNF-α release was measured by specific 
enzyme-linked immunosorbent assay (ELISA). Transfection efficiency was 
greater than 80% (data not shown) and was determined using no-RISC siGLOW 
obtained from Dharmacon (Lafayette, CO).   
 
2.4 Enzyme-linked immunosorbent assay (ELISA) 
 
2.4.1 Cytokines – TNF-α, IL-1β, IL-6, NO 
 After treatment with agents in vitro, cell-free supernatants (culture media) 
were collected, centrifuged, and assayed for the cytokines listed above by R&D 
systems DuoSet™ ELISA kits, in strict accordance with the manufacturer's 
instruction.  Total cell lysate was collected using cell lysis buffer (Cell Signaling 
Technology, Danvers, MA, USA) supplemented with protease inhibitor cocktail 
(Sigma).  Samples were then centrifuged at 14,000 x g for 15 minutes at 4°C.  
BCA protein assay (Thermo Fisher) was performed on collected cell lysate, to 
measure total cellular protein from each of the treatment  groups under 
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consideration.  ELISA results were then normalized to total cellular protein 
(pg/mg).   
Brain tissues collected from in vivo experiments were homogenized using 
total cell lysis buffer (Cell Signaling) with protease inhibitor cocktail (Sigma) 
added.  Samples were centrifuged at 14,000 x g for 30 minutes at 4°C, and cell-
free supernatant removed for ELISA testing and BCA protein assay 
determination.  ELISA testing for the cytokines above was performed using 
DuoSet™ ELISA kits, in strict accordance with the manufacturer's instruction.  
Results are reported as pg of cytokine produced normalized to total protein (mg) 
concentration measured by BCA protein assay.   
 
2.4.2 Soluble and Insoluble Abeta 
Total Aβ1-40,42 species were quantified in samples as previously described 
(Tan et al., 2002).  Briefly, 96-well immunoassay plates were coated with 
monoclonal anti-Aβ1-17 antibody (6E10; 2 µg/mL in PBS; Signet Laboratories, 
Dedham, MA, USA) overnight at 4 °C.  Plates were washed with 0.05% Tween 
20 in PBS 5 times and incubated with blocking buffer (PBS with 1% bovine serum 
albumin (BSA), 5% horse serum) for 2 hours at room temperature.  Samples in 
the form of brain homogenates, or standards were added to the plates, and 
incubated overnight at 4°C.  Following 3 washes, biotinylated anti-Aβ17–26 
monoclonal antibody (4G8; 0.5 µg/mL in PBS with 1% BSA; Signet Laboratories), 
was added to the plates and incubated for 2 hours at room temperature. After 5 
washes, streptavidin-horseradish peroxidase (HRP) (1:200 diluted in PBS with 
 25
1% BSA) was added to the 96-well plates for 30 minutes at room temperature. 
After 3 washes, Tetramethylbenzidine (TMB) substrate was added to the plates 
and incubated for 15 minutes at room temperature.  Stop solution (2N H2SO4) 
was added to stop the colorimetric reaction and optical density was determined 
immediately by a microplate reader at 450 nm.  ELISA values were reported as 
% control or pg of Aβ1-x/mg of total protein, as determined by BCA assay. 
 
2.5 Western Blot 
 
2.5.1 Receptors 
Murine primary culture microglial cells were plated in 6-well tissue culture 
plates (Nunclon™) at a density of 8×105 cells/well. For examining α7 nAChR 
subunit expression, 24h after plating, cells were harvested for preparation of cell 
lysates as described below.  Immediately following culturing, microglial cells were 
washed in ice-cold PBS and lysed in an ice-cold lysis buffer (Tan et al. 2000a). 
After incubating for 30min on ice, samples were centrifuged at high speed for 
15min, and supernatants were collected. Total protein content was estimated 
using the BCA protein assay.  An aliquot of each sample corresponding to 50 
µg of total protein was separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS–PAGE) and transferred electrophoretically to Immun-
Blot™ polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA).  Non-
specific antibody binding was blocked with 5% non-fat dry milk in Tris-buffered 
saline (20 mm Tris, 500 mm NaCl, pH 7.5) for 1h at room temperature.  
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Membranes where first hybridized with a rabbit polyclonal primary antibody 
against α7 subunit of nAChR  stripped with β-mercaptoethanol stripping solution 
(62.5 mm Tris–HCl, pH 6.8; 2% SDS, and 100mm β-mercaptoethanol), and then 
re-probed with a primary antibody that recognizes actin.  The Immun-Star™ 
chemiluminescence substrate (Bio-Rad, Hercules, CA, USA) was used to 
develop the blots.  All blots were imaged using Kodak BioMax maximum 
sensitivity scientific imaging film (Rochester, NY, USA).   
Murine microglial cell lysates (including primary cultured microglial cells) 
were prepared in ice-cold lysis buffer (20 mM Tris, pH 7.5,150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 
glycerolphosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, and 1 mM PMSF) and 
protein concentration was determined by the BCA protein assay as previously 
described (Tan et al. 2000a).  An aliquot corresponding to 50 μg of total protein 
of each sample was separated by SDS-PAGE and transferred electrophoretically 
to immunoblotting PVDF membranes. Nonspecific antibody binding was blocked 
with 5% nonfat dry milk for 1 hr at room temperature in Tris-buffered saline (20 
mM Tris and 500 mM NaCl, pH 7.5). Subsequently, these membranes were first 
hybridized with the goat anti-CB2 antibody (1:100 dilution; Santa Cruz) for 2 hr 
and then washed 3 times in TBS and immunoblotted using an anti-goat HRP-
conjugated IgG secondary antibody as a tracer (Pierce Biotechnology, Inc. 
Rockford, Illinois). The Immun-Star™ chemiluminescence substrate (Bio-Rad, 
Hercules, CA, USA) was used to develop the blots.  To demonstrate equal 
loading, the same-membranes were then stripped with β-mercaptoethanol 
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stripping solution (62.5 mM Tris-HCl, pH 6.8,2% SDS, and 100 mM β-
mercaptoethanol), and finally re-probed with mouse monoclonal antibody to β-
actin (Pierce Biotechnology, Inc.). 
 
2.5.2 p38 and p44/42 MAPK phosphorylation 
 Murine primary culture microglial cells were plated in 6-well tissue culture 
plates (Nunclon™) at a density of 8×105 cells/well.  For examining p44/42 and 
p38 MAPKs, these cells were pre-treated with ACh or nicotine in the presence or 
absence of α-bungarotoxin for 30min as stated above and then incubated with 
LPS for various time points.  Immediately following culturing, microglial cells were 
washed in ice-cold PBS and lysed in an ice-cold lysis buffer.  After incubating for 
30min on ice, samples were centrifuged at 14 000 rpm and 4˚C for 15min, and 
supernatants were collected.  Total protein content was estimated using the BCA 
protein assay.  An aliquot corresponding to 50µg of total protein of each sample 
was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS–PAGE) and transferred electrophoretically to Immun-Blot™ polyvinylidene 
difluoride membranes.  Non-specific antibody binding was blocked with 5% non-
fat dry milk in Tris-buffered saline (20 mm Tris, 500mm NaCl, pH 7.5) for 1h at 
room temperature.  Membranes where first hybridized phospho-specific p44/42 
or p38 MAPK monoclonal antibody, stripped with β-mercaptoethanol stripping 
solution (62.5 mm Tris–HCl, pH 6.8; 2% SDS, and 100mm β-mercaptoethanol), 
and then re-probed with an antibody that recognizes total p44/42 or p38 MAPK. 
Alternatively, membranes with identical samples were probed with either 
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phospho-specific p44/42 or p38 antibody or with an antibody that recognizes total 
p44/42 or p38 MAPK.  Immunoblotting was carried out with a primary antibody 
followed by an anti-rabbit or anti-mouse HRP-conjugated IgG secondary antibody 
as a tracer.  The Immun-Star™ chemiluminescence substrate was used to 
develop the blots. 
 
2.5.3 JAK/STAT1 phosporylation 
Primary culture microglial cells were plated in 6-well tissue culture plates 
at a density of 5 × 105 cells per well and co-incubated with IFN-γ (100 U/mL) in 
the presence or absence of a dose range of CB2 agonist (0.31, 0.62, 1.25, 2.5 
and 5.0 μM) for 30 min.  At the end of the treatment period, microglial cells were 
washed in ice-cold PBS three times and lysed in ice-cold lysis buffer. After 
incubation for 30 min on ice, samples were centrifuged at 14 000 rpm and 4˚C for 
15 min, and supernatants were collected.  Total protein content was estimated 
using the BCA protein assay.  For phosphorylation of JAK1 and JAK2, 
membranes were first hybridized with phospho-specific Tyr1022/1023 JAK1 or 
Tyr1007/1008 JAK2 antibody (Cell Signaling Technology, Beverly, MA) and then 
stripped and finally analyzed by total JAK1 or JAK2 antibody.  For STAT1 
phosphorylation, membranes were probed with a phospho-Ser727 STAT1 
antibody (Cell Signaling Technology) and stripped with stripping solution and 
then re-probed with an antibody that recognizes total STAT1 (Cell Signaling 
Technology).  Alternatively, membranes with identical samples were probed 
either with phospho-JAK or STAT1, or with an antibody that recognizes total JAK 
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or STAT1.  Immunoblotting was performed with a primary antibody followed by 
an anti-rabbit HRP-conjugated IgG secondary antibody as a tracer.  After 
washing in TBS the membranes were incubated in Immun-Star™ 
chemiluminescence substrate  
 
2.5.4 Aβ  
For immunoblot detection of cell-associated Aβ, primary microglial cells 
were plated in 6-well tissue culture plates with glass inserts at 2 × 105 cells/well.  
Aβ1–42 peptide, purity greater than 95% according to manufacturer's high 
performance liquid chromatography (HPLC) analysis, was obtained from QCB 
(Hopkinton, MA). Aβ1–42 peptide used for all experiments was made 
fibrillar/aggregated.  Briefly, 2 mg of Aβ1–42 was added to 0.9 ml of pure water 
(Sigma), the mixture vortexed, and 100 μl of 10X  PBS (1X PBS contains 0.15 M 
NaCl, 0.01 M sodium phosphate, pH 7.5) was added and the solution was 
incubated at 37°C for 24 hr.  The following day, microglial cells were treated with 
Aβ1–42 (3 μM) and CD40L protein (2.5 μg/mL) in the presence or absence of CB2 
agonist (5 μM) for 3 hr.  Microglial cells were then rinsed 3 times in Aβ1–42-free 
complete medium and the medium was exchanged with fresh Aβ1–42-free 
complete medium for 10 min both to allow for removal of unincorporated Aβ1–42 
and to promote concentration of the Aβ1–42 peptide into phagosomes.  
Immunoblotting was carried out with the monoclonal antihuman Aβ antibody 
(BAM-10, 1:1,000 dilution; Sigma) followed by an anti-mouse IgG-HRP as a 
tracer. Blots were developed using the Immun-Star chemiluminescence 
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substrate. The membranes were stripped and then reprobed with a reference 
anti-mouse β-actin monoclonal antibody, which allows for quantification of the 
band density ratio of Aβ to β-actin by densitometric analysis. 
 
2.6 Flow cytometric analysis of microglial CD40 expression 
Primary cultured microglial cells were plated in 6-well tissue culture plates 
at 5 × 105 cells/well and incubated with THC, CP55940 or CB2 agonist (JWH-
015) at different doses in the presence or absence of IFN-γ (100 U/ml).  Twelve 
hours after incubation, these microglial cells were washed with flow buffer [PBS 
containing 0.1% (w/v) sodium azide and 2% (v/v) FCS] and re-suspended in 250 
μl of ice-cold flow buffer for fluorescence activated cell sorting (FACS) analysis.  
Briefly, cells were pre-incubated with anti-mouse CD16/CD32 monoclonal 
antibody (clone 2.4G2, PharMingen, Los Angeles, CA) for 10 min at 4°C to block 
non-specific binding to Fc receptors.  Cells were then spun down at 5,000 g 
washed 3 times with flow buffer and then incubated with hamster anti-mouse 
CD40-FITC or isotype control antibody-FITC (1:100 dilution; PharMingen) in flow 
buffer.  After 30 min incubation at room temperature, cells were washed twice 
with flow buffer, re-suspended in 250 μL of flow buffer and analyzed by a 
FACScan™ instrument (Becton Dickinson, Franklin Lanes, NJ).  A minimum of 
10,000 cells were accepted for FACS analysis.  Cells were gated based on 
morphological characteristics such that apoptotic and necrotic cells were not 
accepted for FACS analysis using CellQuest™ software (Beckton Dickinson).  
Percentages of positive cells (i.e. CD40-expressing) were calculated as follows: 
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for each treatment, the mean fluorescence value for the isotype-matched control 
antibody was subtracted from the mean fluorescence value for the CD40-specific 
antibody.  
 
2.7 Tissue Staining 
 
2.7.1 Immunofluorescence 
 Primary cultured microglial cells (as described above) were passed in 24-
well tissue culture plates at 5 × 104 cells per well, and then cultured for 18 h.  
This culture then went untreated (control) or was pre-treated with nicotine (500 
µm; Wang et al. 2003) at 37°C for 15 min and then incubated with FITC-labeled 
α-bungarotoxin (1.5 µg/mL; Wang et al. 2003) at 4°C for 15 min.  Immediately 
following incubation, these cells were washed with RPMI medium three times 
and then fixed for 15 min in 4% paraformaldehyde–phosphate-buffered saline 
(PBS) solution at room temperature.  After fixation, these cells were washed 
once with PBS for viewing by fluorescent microscope (Inverted microscope, 
IX71/IX51 Olympus, Tokyo, Japan). 
 
2.7.2 Immunohistochemical 
Six mice (three male and three female, 10 weeks old; ICR, Crea Japan, 
Tokyo, Japan) were used to examine the in situ expression of α7 nAChR in the 
mouse brain.  After mice were killed with sodium pentobarbital (50 mg/kg), brains 
were perfused transcardially with 200 mL of 10 U/mL heparin in saline followed 
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by 200 mL of 4% paraformaldehyde in 0.1 m (pH 7.4) PBS.  The brain was 
removed and fixed in the same fixative for overnight at 4°C, dehydrated, and 
routinely embedded in paraffin with 16 h of processing.  Sections were cut with 5-
µm in thickness.  For detecting α7 nAChR in situ, sections were deparaffinized 
and pre-treated by hydrolytic autoclaving in 10mm citrate buffer (pH 6.0) for 
30min at 121°C to retrieve antigens.  Thereafter, sections were treated with 
endogenous peroxidase quenching (0.3% H2O2 for 10min) and pre-blocked with 
serum-free blocking solution (Dako, Kyoto, Japan) for 30min prior to primary 
antibody incubation.  Immunohistochemistry was performed according to the 
manufacturer's protocol using the Vectastain ABC elite kit (Vector Laboratories, 
Burlingame, CA, USA) coupled with the diaminobenzidine reaction.  Rabbit anti-
human α7 nAChR polyclonal antibody (1:200 dilution) was employed as the 
primary antibody for 2h at room temperature.  PBS or normal rabbit serum 
(isotype control) was used instead of primary antibody or ABC reagent as a 
negative control.  Neuronal signal was used as a putative positive control. 
Six mice (10 weeks of age, 3 male/3 female, C57 BL/6N; Crea, Tokyo, 
Japan) were used to examine the expression of CB2 in microglial cells.  After 
mice were euthanized with an overdose of sodium pentobarbital (50 mg/kg), the 
brain was perfused transcardially with 200 mL of 10 U/mL heparin in saline 
followed by 200 mL of 4% paraformaldehyde in 0.1 M (pH 7.4) PBS.  The brains 
were removed and fixed in the same fixative overnight at 4°C, dehydrated, and 
routinely embedded in paraffin with 16 hr processing.  For in situ detection of 
CB2, sections (5 μm in thickness) were deparaffinized and pretreated by 
 33
hydrolytic autoclaving in 10 mM citrate buffer (pH 6.0) for 15 min at 121°C to 
retrieve antigens.  Thereafter, sections were treated with endogenous peroxidase 
quenching (0.3% H2O2 for 10 min) and pre-blocked with serum-free blocking 
solution (DAKO, Carpinteria, CA) for 30 min prior to primary antibody incubation. 
Immunohistochemistry was performed according to the manufacturer's protocol 
using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA) coupled 
with the diaminobenzidine reaction.  For double labeling of CB2 and Iba-1 
(microglial cell marker) in frozen sections, an additional six mice were euthanized 
with the same anesthesia as above, and then the brains were perfused 
transcardially with 200 mL of 10 U/mL heparin in saline.  Brains were quick-
frozen at -80°C for cryo-sectioning (25 μm in thickness).  Prior to 
immunohistochemistry, frozen sections were fixed with 4% paraformaldehyde in 
0.1 M (pH 7.4) PBS for 1 hr, and pre-blocked with serum-free blocking solution 
(DAKO, Carpinteria, CA) for 30 min.  The following primary and secondary 
antibodies were used: goat anti-mouse CB2 antibody (1:400 dilution; Santa Cruz 
Biotechnologies), rabbit anti-C-terminus of Iba-1 antibody (1:500 dilution; Wako 
Pure Chemical Industries, Osaka, Japan), FITC-conjugated donkey anti-goat IgG 
(1:50 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA), and 
TRITC-conjugated swine anti-rabbit IgG (1:50 dilution; DAKO, Carpinteria, CA). 
In addition, for a neutralization test (pre-absorption test), goat anti-mouse CB2 
antibody was pre-incubated for 30 min with a fivefold (w/v) excess of mouse CB2 
blocking peptides (Santa Cruz Biotechnologies). Whereas the appropriate 
isotype control serum or PBS was used instead of primary antibody or ABC 
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reagent as a negative control, spleen was used as a positive control. 
Counterstaining was performed with hematoxylin. 
 
2.8 Microglial Aβ phagocytosis assay 
Aβ1–42 peptide, purity greater than 95% according to manufacturer's high 
performance liquid chromatography (HPLC) analysis, was obtained from QCB 
(Hopkinton, MA). Aβ1–42 peptide used for all experiments was made 
fibrillar/aggregated, as previously described (Tan et al., 2000a).  Briefly, 2 mg of 
Aβ1–42 was added to 0.9 ml of pure water (Sigma), the mixture vortexed, and 100 
μl of 10X  PBS (1X PBS contains 0.15 M NaCl, 0.01 M sodium phosphate, pH 
7.5) was added and the solution was incubated at 37°C for 24 hr. The Cy3-Aβ 
peptide's conjugation was carried out in strict accordance with the manufacturer's 
described protocols. Briefly, Aβ1–42 was dissolved in 0.15 M sodium chloride and 
Cy3 mono-reactive NHS ester (Amersham Biosciences, Piscataway, NJ) was 
diluted in dimethyl sulfoxide (DMSO) to a working concentration of 10 mg/mL and 
this was slowly added to the Aβ1–42 solution while stirring. The Cy3-Aβ1–42 
solution was protected from light while stirred for 45 min at room temperature.  
To separate the free Cy3-dye, the solution was dialyzed against 1 L of 0.15 M 
sodium chloride for 4 hr at room temperature. The solution was then exchanged 
with fresh 0.15 M sodium chloride and dialyzed overnight at 4°C.  The next day 
the Cy3-β1–42 solution was dialyzed against 1 L of 0.1 M PBS for 4 hr at room 
temperature, and again dialyzed overnight using fresh 0.1 M PBS. The solution 
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was then syringe-filter sterilized through a 0.22-μm filter and the eluate was 
aliquoted and stored at -20°C until used.  
Microglial cells were cultured at 2 × 105/well in 6-well tissue-culture plates 
with glass inserts (for fluorescence microscopy). The following day, microglial 
cells were treated with Cy3-conjugated Aβ1–42 (3 μM) and CD40L protein (2.5 
μg/mL) in the presence or absence of CB2 agonist (5 μM) for 3 hr. In parallel 
dishes, microglial cells were incubated with Cy3-conjugated Aβ1–42 under the 
same treatment conditions above except they were incubated at 4°C to control 
for non-specific cellular association of Cy3-Aβ1–42. Microglial cells were then 
rinsed 3 times in Aβ1–42-free complete medium and the medium was exchanged 
with fresh Aβ1–42-free complete medium for 10 min both to allow for removal of 
unincorporated Cy3-Aβ1–42 and to promote concentration of the Cy3-Aβ1–42 
peptide into phagosomes.  This medium was withdrawn and microglial cells were 
rinsed 3 times with ice-cold PBS.  For fluorescence microscopy, microglial cells 
on glass coverslips were fixed for 10 min at 4°C with 4% (w/v) paraformaldehyde 
(PFA) diluted in PBS.  After three successive rinses in TBS, microglial cell nuclei 
were detected by incubation with DAPI for 10 min and finally mounted with 
fluorescence mounting media containing Slow Fade antifading reagent 
(Molecular Probes, Eugene, OR) and then viewed under an Olympus IX71/IX51 
fluorescence microscope equipped with a digital camera system to allow for 
digital capture of images (40×).   
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2.9 Statistical analysis 
All data were normally distributed; therefore, in instances of single mean 
comparisons, Levene’s test for equality of variances followed by a t test for 
independent samples was used to assess significance.  If multiple mean 
comparisons were made, analysis of variance ANOVA was used, followed by 
post hoc comparison using Bonferonni’s method.  α-levels were set at 0.05 for all 
analyses. The statistical package for the social sciences release 10.0.5 (SPSS 
Inc., Chicago, IL, USA) or Statistical (StatSoft Inc., Tulsa, OK, USA) was used for 
all data analysis. 
  
 
CHAPTER 3 
 
CHOLINERGIC MODULATION OF MICROGLIAL ACTIVATION BY α7 
NICOTINIC RECEPTORS 
 
3.1 The nAChR and neurodegenerative disease 
Over the last several years there has been a rapid accumulation of 
evidence suggesting that neuronal nicotinic acetylcholine receptors (nAChR) play 
important roles in neurodegenerative diseases (O’Neill et al. 2002).  First, there is 
a well established loss of nAChR in post-mortem brains from patients with 
Alzheimer’s disease (AD; Burghaus et al. 2000), Parkinson’s disease (PD; Guan 
et al. 2002), and a range of other neurodegenerative disorders (Leonard et al. 
2000; Engidawork et al. 2001).  This loss is generally more substantial than the 
reduction found in muscarinic cholinergic receptors (Nordberg et al. 1992) and 
contrasts, perhaps in a functionally relevant way, with the higher density of 
nAChRs reported present in the brain of normal smokers (Perry et al. 1999). 
Second, epidemiologic studies have reported a consistent inverse relationship 
between nicotine intake (tobacco smoking) and the incidence of both PD (Morens 
et al. 1995) and AD (Brenner et al. 1993), suggesting that smoking may be 
neuroprotective.  Third, the degree of cognitive impairment found in AD 
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correlates well with the central cholinergic deficiency, and treatment with nAChR 
agonists elicit long-lasting improvement of cognitive performance in aging 
animals and humans (Newhouse et al. 1997; Terry and Buccafusco 2003).  
Considerable empirical evidence suggests that nicotine is neuroprotective in 
animal models of neurodegenerative disorders (Shytle et al. 2000; O’Neill et al. 
2002).  Both in vitro and in vivo, nicotine protects striatal, hippocampal, and 
cortical neurons against the neurotoxicity induced by excitotoxic amino acids as 
well as the toxicity caused by β-amyloid, the major component of senile plaques 
of AD.  A variety of neuronal mechanisms, including the production of growth 
factors such as fibroblast growth factor (Belluardo et al. 2000), reduction of 
superoxide anion generation in brain mitochondria (Cormier et al. 2003), and 
antioxidant actions (Guan et al. 2003;Newman et al. 2002), have been proposed 
as possible mechanisms for nicotine-mediated neuroprotection.  One area that 
has received little attention is the role of nAChR function in neuroimmunology.  
Most neurodegenerative diseases are connected to chronic inflammation and a 
central step in this process is the activation of brain mononuclear phagocyte 
cells, called microglia (Polazzi and Contestabile 2002).  While an important role 
of microglial cells is to support and sustain proper neuronal function, under 
certain pathophysiological conditions, microglia can remain in the activated state 
for a prolonged period of time in which they secrete various inflammatory factors 
(Streit 2000).  The latter in turn can produce neuronal dysfunction and 
degeneration (Tan et al. 2002; Liu and Hong 2003).  In the peripheral nervous 
system, recent studies suggest that the vagus nerve acts as an endogenous 
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‘cholinergic anti-inflammatory pathway’ that regulates systemic inflammatory 
responses by modulating α7 receptors on blood-borne macrophages (Wang et al. 
2003).  To determine whether a similar endogenous ‘cholinergic anti-
inflammatory pathway’ exists in the brain, we first examined the expression of 
microglial α7 nAChR in vitro and in vivo, and then investigated its functional role 
in regulation of microglial activation induced by lipopolysaccharide (LPS).  
Furthermore, we investigated whether its function could be associated with 
modulation of phosphorylation of p44/42 and p38 mitogen-activated protein 
kinase (MAPK).   
 
3.2 Materials and Methods 
 
3.2.1 Reagents 
 The following chemicals were obtained from Sigma (St Louis, MO, USA): 
nicotine ([-]-1-methyl-2-[3-pyridyl]-pyrrolidine), acetylcholine chloride, α-
bungarotoxin; fluorescein isothiocyanate (FITC)-labeled α-bungarotoxin, and 
mecamylamine HCl.  Rabbit polyclonal antibodies against the carboxy terminus 
of the α7 subunit of the nicotinic acetylcholine receptor were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).  DuoSet enzyme linked 
immunoabsorbance assay (ELISA) TNF-α kit was obtained from R&D System 
(Minneapolis, MN, USA).  Antibodies for phospho-p44/42 MAPK(Thr202/T 
yr204), phosphor-p38 (Thr180/Tyr182), and total p44/42, p38 MAPKs were 
obtained from New England Biolabs (Beverly, MA, USA).  The anti-mouse and 
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anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibodies were 
purchased from New England Biolabs.  Immun-Blots ployvinylidene difluoride 
(PVDF) membranes and the Immun-Star chemiluminescence substrate were 
purchased from Bio-Rad (Hercules, CA, USA). 
 
3.2.2 Murine primary cell culture 
 Primary cultured microglial cells were isolated from mouse cerebral 
cortices (C57BL/6 mice, The Jackson Laboratory) and were grown in RPMI 
medium supplemented with 5% fetal calf serum, 2 mM glutamine, 100 units/μL 
penicillin, 0.1 μg/mL streptomycin, and 0.05 mM 2-mercaptoethanol as previously 
described (Tan et al. 2000a).  Cells were plated in 24 well tissue culture plates 
and pretreated with nicotine or acetylcholine for 30min.  LPS was then added to 
the wells and incubated for 4hrs at 37ºC.  Media was collected and assayed for 
pro-inflammatory cytokines, while cell lysate was assayed for total protein 
concentration. 
 
3.2.3 RT-PCR analysis 
 Total RNA was isolated from primary cultured microglial cells using a 
single extraction method (TRIZOL reagent, Gibco-BRL, Grand Island, NY, USA) 
and cDNA was synthesized using a cDNA cycle kit (Invitrogen, Carlsbad, CA, 
USA).  PCR was performed for 30 cycles, with each cycle consisting of 94°C for 
1 min, 55°C for 2 min, and 72°C for 2 min, followed by a final extension step at 
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72°C for 10 min. PCR products were resolved on 1.2% ethidium bromide-stained 
agarose gels, and visualized by ultraviolet transillumination. 
 
3.2.4 Fluorescent staining analysis 
 Primary cultured microglial cells were passed in 24-well tissue culture 
plates and then incubated for 18 h.  This culture then went untreated (control) or 
was pre-treated with nicotine (500 μM; Wang et al. 2003) at 37°C for 15 min and 
then incubated with FITC-labeled a-bungarotoxin (1.5 μg/mL; Wang et al. 2003) 
at 4°C for 15 min.  Immediately following the 15 min incubation, cells were 
washed with RPMI medium three times and then fixed for 15 min in 4% 
paraformaldehyde–phosphate-buffered saline (PBS) solution at room 
temperature.  After fixation, these cells were washed once with PBS for viewing 
by fluorescent microscope (Inverted microscope, IX71/IX51 Olympus, Tokyo, 
Japan). 
 
3.2.5 Immunohistochemistry analysis 
 Six mice (three male and three female, 10 weeks old; ICR, Crea Japan, 
Tokyo, Japan) were used to examine the in situ expression of α7 nAChR in the 
mouse brain.  After collecting and fixing the brain tissue in 4% paraformaldehyde 
in 0.1M (pH 7.4) PBS, it was embedded in paraffin. Sections were cut with 5-μm 
in thickness.  For detecting α7 nAChR in situ, sections were deparaffinized and 
pre-treated by hydrolytic autoclaving in 10 mM citrate buffer (pH 6.0) for 30 min 
at 121°C to retrieve antigens.  Thereafter, sections were treated with 
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endogenous peroxidase quenching (0.3% H2O2 for 10 min) and pre-blocked with 
serum-free blocking solution (Dako, Kyoto, Japan) for 30 min prior to primary 
antibody incubation.    Rabbit anti-human α7 nAChR polyclonal antibody (1:200 
dilution) was employed as the primary antibody for 2 h at room temperature.  
PBS or normal rabbit serum (isotype control) was used instead of primary 
antibody or ABC reagent as a negative control.  Immunohistochemistry was 
performed using the Vectastain ABC elite kit (Vector Laboratories, Burlingame, 
CA, USA) coupled with the diaminobenzidine (DAB) reaction. Neuronal signal 
was used as a putative positive control. 
 
3.3 Results 
 
3.3.1 Microglial cells express the α7 nAChR 
Murine primary culture microglial cells were isolated from mouse cerebral 
cortices (C57BL/6 mice) and cultured as previously described (Tan et al. 2000b).  
To investigate whether α7 nAChR subunits are expressed in microglial cells, we 
first isolated total RNA from N9 microglial cell line and primary cultured microglial 
cells for RT–PCR analysis.  Results show that the α7 nAChR subunit mRNA was 
detected in both of these cells (Fig. 3.1a). Further, α7 nAChR subunit protein was 
detected in primary cultured microglial cells by western blot (Fig. 3.1b).  To 
evaluate whether α-bungarotoxin, an α7 nAChR subunit-selective blocker, could 
bind to this receptor, we pre-treated primary microglial cells in the presence or 
absence of nicotine and then incubated with FITC-labeled α-bungarotoxin. As 
shown in Figs 3.2(c and d), nicotine pretreatment resulted in a marked reduction  
 43
  
 
 
Figure 3.1 
α7 nAChR subunit is expressed by microglia.  RT–PCR analysis (A) of N9 
microglial cells and primary cultured microglial cells.  A 410-bp band 
corresponding to α7 subunit was specifically generated with primers (sense: 5’-
GGCCAACGACTCGCAGCCGCTC-3’; and antisense: 5’-
GCAGGTCCAAGGACCACCCTC-3’; (Kuo et al. 2002).  Western immunoblotting 
analysis (B) of a7 nAChR protein in N9 microglial cells and murine primary 
cultured microglial cells. 
 
 
 
 44
of fluorescent intensity of FITC-labeled α-bungarotoxin binding compared to the 
absence of nicotine (Figs 3.2a and b). In order to gain further insight into the 
expression of α7 nAChR in situ, we performed immunohistochemistry on adult 
mouse brain and found that microglial cells stain positively for α7 nAChR subunit 
(Fig. 3.2e).  To rule out the possibility of non-specific binding, PBS was used 
instead of primary antibody as a negative control (Fig. 3.2f).  Additionally, we also 
stained cells using normal rabbit serum (the appropriate isotype control) instead 
of rabbit anti-α7 nAChR primary antibody and results were similar to the PBS-
negative control (data not shown).   
 
3.3.2 Stimulation of α7 receptors on microglia reduces cytokine production 
ACh or nicotine pre-treatment resulted in a marked reduction of LPS-induced 
TNF-α release (Fig. 3.3a).  Co-pretreatment with selective α7 nAChR antagonist, 
α-bungarotoxin or non-selective nAChR antagonist, mecamylamine, significantly 
blocked Ach or nicotine-mediated inhibition of TNF-α production (Fig. 3.3a).  
Furthermore, ACh or nicotine pre-treatment alone inhibited TNF-α production in a 
concentration-dependent manner (Figs 3.3b and c).  In order to test the 
possibility of whether nicotine may reduce microglial activation induced by other 
stimuli, such as HIV-1 gp120 (Albright et al. 2001), we pre-treated cultured 
microglial cells with nicotine and then challenged these cells with HIV-1 gp120 (1 
μg/mL) in the presence of IFN-γ (100 U/mL).  Data showed that nicotine pre-
treatment significantly attenuated microglial activation as evidenced by 
decreased TNF-α production (data not shown). 
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Figure 3.2 
Microglial α7 nAChR expression is examined by fluorescent and 
immunohistochemistry staining analysis.  Primary cultured microglial cells were 
pre-incubated in the absence (a, 20X b, 40X) and presence (c, 20X; d, 40X) of 
nicotine (500 μM) for 15 min before adding FITC-labeled α-bungarotoxin (α-Bgt, 
1.5 μg/mL) for 15 min at 4°C.  Immunohistochemistry was performed on cerebral 
paraffin sections of normal mouse brain temporal cortices with the antigen 
retrieval method in the presence (e) or absence (d, counterstaining was 
performed with hematoxylin) of rabbit anti-α7 nAChR primary antibody.  Bars 
denote 20 μm.  Note positively immunolabeled-microglia (arrowhead) and 
neurons (positive control). 
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Figure 3.3 
Microglial α7 nAChR subunit is functional. As indicated (a), primary cultured 
microglial cells were pre-stimulated for 30 min with Ach (5 μM) or nicotine (5 μM) 
in the presence or absence of α7 nAChR antagonists, α-Bgt (10 nM); 
mecamylamine (MEC) 10 μM and challenged with LPS (100 ng/mL) for 4 h. TNF-
α release in cell-free supernatants was assayed by ELISA kit. ANOVA revealed 
significant main effects of an interaction between LPS and ACh plus LPS 
(ACh/LPS) (p < 0.01) or nicotine plus LPS (Nic/LPS) (p < 0.01). One-way 
ANOVA revealed significant between-group differences (p < 0.01), and posthoc 
testing showed significant differences between ACh/LPS and ACh/α-Bgt/LPS (p 
< 0.01), and between Nic/LPS and Nic/α-Bgt/LPS (p < 0.01), as well as between 
ACh/LPS and ACh/MEC/LPS (p < 0.01), and between Nic/LPS and 
Nic/MEC/LPS (p < 0.01). However, no significances were noted between LPS 
and α-Bgt/LPS (p > 0.05), or between LPS and MEC/LPS (p > 0.05). Primary 
cultured microglial cells pre-treated with ACh (b) or nicotine (c) at a range of dose 
as indicated for 30 min and challenged with LPS (100 ng/mL) for 4 h, dose-
dependently inhibited microglial LPS-induced TNF-α production. One-way 
ANOVA across doses revealed significant between- groups differences (p < 
0.01). 
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3.3.3 α7 reduces LPS induced activation through inhibition of MAPKs 
 Because previous studies have shown that activation of MAPK p44/42 and 
p38 is involved in TNF-α production in activated microglia (Tan et al. 2002), we 
analyzed p44/42 and p38 MAPK phosphorylation status in microglial cell lysates 
after pre-treatment with ACh or nicotine for 30 min and then challenge with LPS 
at various time points.  Results showed that pre-treatment with either ACh or 
nicotine significantly inhibited phosphorylation of p44/42 and p38 MAPK induced 
by LPS compared with controls (Figs 3.4a and b).  We also pre-treated microglial 
cells with ACh or nicotine in the presence or absence of α-bungarotoxin.  Thirty 
minutes later these cells were challenged with LPS.  Phosphorylation status of 
p44/42 and p38 MAPK were examined by western blot.  As shown in Figs 3.4(c 
and d), this co-pre-treatment attenuated ACh- or nicotine-mediated inhibition of 
phosphorylation of p44/42 and p38 MAPK induced by LPS.  Consistently with 
previous studies demonstrating that p44/42 and p38 MAPK are important for 
microglial TNF-α production (Tan et al. 2002), our data show that 
phosphorylation of these MAPKs is markedly reduced in Ach- or nicotine-pre-
treated microglial cells following LPS challenge.  In addition, we and others have 
previously demonstrated that inhibition of MAPK phosphorylation by either 
SB203580 (a p38 MAPK inhibitor), or PD98059 (a MEK1/2 inhibitor) results in a 
reduction of microglial TNF-α production induced by CD40 ligation (Tan et al. 
1999b, 2000a) or other stimuli (such as LPS; Fiebich et al. by 2002; Jeohn et al. 
2002).   
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3.4 Conclusions 
The studies detailed in this chapter qualify the α7 receptor, a unique 
member of the nicotinic acetylcholine receptor family, as having potent anti-
inflammatory properties.  Nicotine is able to mitigate the LPS-induced microglial 
TNF-α production via stimulation of α7-associated cholinergic pathway involving 
the MAPKs.  Microglia, the resident immune cells of the brain, readily express 
this receptor as observed through RT-PCR western blotting, as well as 
immunohistochemical studies.  Also, indirect observation of the expression of α7 
was identified using a FITC-labeled form of the receptor specific antagonist α-
bungarotoxin.  Physiologically relevant concentrations of ACh and nicotine were 
able to modulate microglial TNF-α release evoked by LPS through activation of 
the α7 nAChR.  MAPK phosphorylation plays a central role in the signaling 
cascade resulting in the immunogenic effects of LPS on microglia.  Activation of 
α7 receptors, using nicotine or acetylcholine, prevented the phosphorylation of 
both p44/42 and p38 MAPK, and thus inhibited the LPS induced signaling 
cascade.  To further verify that these effects on MAPK phosphorylation are 
through the α7 receptor, additional studies employing the use of α-bungartoxin 
were investigated.  Administration of this α7 receptor specific antagonist blocked 
the reduction in p44/42 and p38 MAPK phosphorylation that was observed earlier 
form by nicotine and acetylcholine.  Taken together, these data suggest that the 
downstream mechanism of this central α7 cholinergic anti-inflammation pathway 
is associated with inhibition of phosphorylation of p44/42 and p38 MAPK.  
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CHAPTER 4 
 
STIMULATION OF CANNABINOID RECEPTOR 2 (CB2) SUPPRESSES 
MICROGLIAL ACTIVATION 
 
4.1 Cannabinoid receptors and neurodegenerative disease 
Most neurodegenerative diseases are associated with chronic 
inflammation resulting from the activation of brain mononuclear phagocytic cells, 
called microglia (Polazzi and Contestabile. 2002).  Factors mediating microglial 
activation are of intense interest because increased proliferation of microglial 
cells is seen in the brains of patients with multiple sclerosis (MS) (Schonrock et 
al. 1998), Alzheimer's disease (AD) (Mackenzie et al. 1995), and HIV 
(Gendelman and Tardieu. 1994); and because sustained microglial activation 
associated with these diseases is known to have deleterious effects on the 
surrounding neurons (Nelson et al. 2002), factors mediating microglial activation 
are of intense interest. 
Marijuana and its active constituent, ∆9-tetrahydrocannabinol (∆9-THC), 
suppress cell-mediated immune responses (for review, see Klein et al. (2003).  
Many of these effects are mediated by the cannabinoid receptor 2 (CB2), as 
demonstrated by the finding that THC inhibits helper T-cell activation by normal, 
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but not CB2 knockout-derived, macrophages (Buckley et al. (2000).  While many 
studies have investigated effects the of cannabinoids on immune function, few 
studies have examined their effects on the CD40 pathway (Schonbeck and 
Libby. 2001). 
The CD40 receptor is a 50 kDa type-I phosphoprotein member of the 
tumor necrosis factor (TNF)-receptor (TNFR) superfamily which is expressed by 
a wide variety of cells (Schonbeck and Libby. 2001).  The ligand for CD40 
(CD154, i.e. CD40L) is mainly expressed by activated CD4+ T-cells.  Following 
ligation of CD40, numerous cell-type-dependent signaling pathways are 
activated, leading to changes in gene expression and function.  These changes 
include several signal transduction pathways: such as nuclear factor kappa-B 
(NF-κB), mitogen-activated protein (MAP) kinases, TNF-R associated factor 
proteins, phosphatidylinositol-3 kinase (PI3K), and the Janus kinase (JAK)/signal 
transducer and activator of transcription 1 (STAT1) pathway. (van Kooten. 2000, 
van Kooten and Banchereau. (2000).  Ligation of CD40 on microglial cells leads 
to the production of TNF- α and other compounds that have been identified as 
possible neurotoxins (Fisher and Reichmann. 2001).  Thus, signaling through 
CD40 on microglial cells induces soluble mediators that could have important 
functional roles in the central nervous system (CNS). 
In the normal brain environment, microglial cells display a quiescent 
phenotype, including low CD40 expression (Tan et al. 1999).  However upon 
insult to the brain, microglial cells become highly activated, altering their 
phagocytic and antigen presentation functions (Townsend et al. 2005) as well as 
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the production of cytokines (Aloisi. 2001).  Expression if CD40 is also elevated in 
response to these inflammatory signals.  Mounting evidence implicates microglial 
CD40 as contributing to the initiation and/or progression of several 
neurodegenerative diseases (Townsend et al. 2005).  In fact, blocking CD40-
CD154 interactions by a neutralizing antibody strategy prevents murine 
experimental autoimmune encephalomyelitis (EAE) disease activity (Howard et 
al. 2003) as well as AD-like pathology in mouse models of the disease (Tan et al. 
2002). 
 Given the recently described immunomodulatory role of cannabinoids, the 
importance of CD40-CD40L interaction in neuroinflammatory diseases, and the 
clinical and basic science studies suggesting that cannabinoids may be 
therapeutic in AD and MS, (Ramirez et al. 2005, Zajicek et al. 2003), we 
examined, in the present study, whether cannabinoids (primarily CB2 agonist 
JWH-015) could oppose microglial CD40 expression following interferon-γ (IFN-
γ) challenge.  Furthermore, we examined whether CB2 agonist JWH-015 
influences microglial phagocytic function and/or proinflammatory cytokine 
production after CD40 ligation. 
 
4.2 Materials and methods 
 
4.2.1 Reagents 
Aβ1–42 peptide, purity greater than 95% according to manufacturer's HPLC 
analysis, was obtained from QCB (Hopkinton, MA).  Aβ1–42 peptide used for all 
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experiments was made fibrillar/aggregated, as previously described (Tan et al., 
2000a).  Non-selective cannabinoid agonist CP 55,940, CB2 agonist JWH-015, 
and THC were obtained from Tocris (Ellisville, MO) and dissolved in 1% DMSO 
to a stock concentration of 50 mM. 
 
4.2.2 Animals and microglial cell cultures 
Breeding pairs of BALB/c mice were purchased from Jackson Laboratory 
(Bar Harbor, ME) and housed in the animal facility at the University of South 
Florida, College of Medicine.  Murine primary culture microglial cells were 
isolated from mouse cerebral cortices and grown in RPMI 1640 medium 
supplemented with 5% fetal calf serum (FCS), 2 mM glutamine, 100 U/ml 
penicillin, 0.1 μg/ml streptomycin, and 0.05 mM 2-mercaptoethanol according to 
previously described methods (Tan et al,. 2000).  After isolation, more than 98% 
of these glial cells stained positive for microglial marker Mac-1 (CD11b/CD18; 
Boehringer Mannheim, Indianapolis, IN; data not shown).  All animal protocols 
were approved by the Committee of Animal Research at the University of South 
Florida, in accordance with the National Institutes of Health guidelines.  N9 
microglial cell line was cultured as previously described (Tan et al. 1999a). 
 
4.2.3 RT-PCR analysis 
Total RNA was isolated from primary cultured microglial cells using Trizol 
reagent (Invitrogen, Carlsbad, CA) as recommended in the manufacturer's 
protocol.  RNA concentration was measured by spectrophotometry at 260 nm.  
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RT-PCR was performed as described previously (Tan et al. 1999a).  The PCR 
primers used were CB2 sense: 5'-CCG GAA AAG AGG ATG GCA ATG AAT-3' 
and antisense: 5'-CTG CTG AGC GCC CTG GAG AAC-3' oligonucleotides were 
designed to produce the partial 239 bp mouse CB2 cDNA (MGI:104650); mouse 
β-actin sense: 5'-TTG AGA CCTTCA ACA CCC-3' and β-actin antisense: 5'-GCA 
GCT CAT AGC TCT TCT-3', which yields the 357 bp β-actin cDNA fragment.  
Samples not undergoing reverse transcription were run in parallel to control for 
technical errors leading to DNA contamination (data not shown).  Mouse β-actin 
was amplified from all samples as a housekeeping gene to normalize expression.  
PCR was performed with each cycle consisting of 94°C for 1 min, 55°C for 2 min, 
and 72°C for 2 min, followed by a final extension step at 72°C for 10 min.  PCR 
cycle numbers were kept low to perform semi-quantitative PCR (actin, 25 cycles; 
CB2 30 cycles).  PCR products were resolved on 1.2% ethidium bromide-stained 
agarose gels, and visualized by ultraviolet transillumination. 
 
4.2.4 Flow cytometric analysis of microglial CD40 expression 
Primary cultured microglial cells were plated in 6-well tissue culture plates 
at 5 × 105 cells/well and incubated with THC, CP55940 or CB2 agonist (JWH-
015) at different doses in the presence or absence of IFN-γ (100 U/ml).  Twelve 
hours after incubation, these microglial cells were washed with flow buffer [PBS 
containing 0.1% (w/v) sodium azide and 2% (v/v) FCS] and re-suspended in 250 
μl of ice-cold flow buffer for fluorescence activated cell sorting (FACS) analysis, 
according to methods described previously (Tan et al. 1999a).  A minimum of 
10,000 cells were accepted for FACS analysis.  Cells were gated based on 
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morphological characteristics such that apoptotic and necrotic cells were not 
accepted for FACS analysis using CellQuest™ software (Beckton Dickinson).  
Percentages of positive cells (i.e. CD40-expressing) were calculated as follows: 
for each treatment, the mean fluorescence value for the isotype-matched control 
antibody was subtracted from the mean fluorescence value for the CD40-specific 
antibody. 
 
4.2.5 Western immunoblotting analysis 
Murine microglial cell lysates (including primary cultured microglial cells) 
were prepared in ice-cold lysis buffer (20 mM Tris, pH 7.5,150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 
glycerolphosphate, 1 mM Na3VO4, 1 υg/ml leupeptin, and 1 mM PMSF) and 
protein concentration was determined by the Bio-Rad protein assay as previously 
described (Tan et al. 1999b).  An aliquot corresponding to 50 μg of total protein 
of each sample was separated by SDS-PAGE and transferred electrophoretically 
to immunoblotting PVDF membranes.  These membranes were first hybridized 
with the goat anti-CB2 antibody (1:100 dilution; Santa Cruz) for 2 hr and then 
washed 3 times in TBS and immunoblotting using an anti-goat HRP-conjugated 
IgG secondary antibody as a tracer (Pierce Biotechnology, Inc. Rockford, Illinois).  
Luminol reagent (Pierce Biotechnology, Inc.) was used to develop the blots.  The 
same-membranes were then stripped with β-mercaptoethanol stripping solution 
(62.5 mM Tris-HCl, pH 6.8,2% SDS, and 100 mM β-mercaptoethanol), and finally 
re-probed with mouse monoclonal antibody to β-actin (Pierce Biotechnology, 
Inc.). 
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4.2.6 Immunohistochemistry analysis 
Six mice (10 weeks of age, 3 male/3 female, C57BL/6N; Crea, Tokyo, 
Japan) were used to examine the expression of CB2 in microglial cells.  After 
mice were euthanized with an overdose of sodium pentobarbital (50 mg/kg), the 
brain was perfused transcardinally with 200 mL of 10 U/ mL heparin in saline 
followed by 200 mL of 4% paraformaldehyde in 0.1 M (pH 7.4) PBS.  The brains 
were removed and fixed in the same fixative overnight at 4°C, dehydrated, and 
routinely embedded in paraffin with 16 hr processing. For in situ detection of CB2, 
sections (5 μm in thickness) were deparaffinized and pretreated by hydrolytic 
autoclaving in 10 mM citrate buffer (pH 6.0) for 15 min at 121°C to retrieve 
antigens. Thereafter, sections were treated with endogenous peroxidase 
quenching (0.3% H2O2 for 10 min) and pre-blocked with serumfree blocking 
solution (DAKO, Carpinteria, CA) for 30 min prior to primary antibody incubation.  
Immunohistochemistry was performed according to the manufacturer's protocol 
using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA) coupled 
with the diaminobenzidine reaction.  For double labeling of CB2 and Iba-1 
(microglial cell marker) in frozen sections, the following primary and secondary 
antibodies were used: goat anti-mouse CB2 antibody (1:400 dilution; Santa Cruz 
Biotechnologies), rabbit anti-C-terminus of Iba-1 antibody (1:500 dilution; Wako 
Pure chemical Industries, Osaka, Japan), FITC-conjugated donkey anti-goat IgG 
(1:50 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA), and 
TRITC-conjugated swine anti-rabbit IgG (1:50 dilution; DAKO, Carpinteria, CA).  
Counterstaining was performed with hematoxylin. 
 57
4.2.7 CB2 small interfering RNA 
N9 cells were transfected with specific murine CB2 targeting siRNA 
designed to knockdown murine CB2 expression (Humesis Biotechnology 
Corporation, New Orleans, LA).  After transfection with 100 nM anti-CB2 siRNA, 
the cells were allowed to recover for 24 hr in complete medium (MEM 10% FBS) 
before treatments.  The cells were evaluated by Western immunodetection for 
the expression of CB2 using anti- CB2 antibodies (Santa Cruz) following siRNA 
treatment.  The cells were also cultured for 4 hr with LPS, JWH-015, or various 
combinations, and TNF-α release was measured by ELISA.  
 
4.2.8 TNF-α and nitric oxide (NO) analyses 
Murine primary cultured microglial cells were plated in 24-well tissue-
culture plates (Costar, Cambridge, MA) at 1×105 cells per well and stimulated for 
24 hr with either IFN-γ (100 U/ml)/CD40L protein (2.5 υg/ml) or Aβ1–42 (3 
μM)/CD40L protein (2 μg/ml) in the presence or absence of CB2 agonist JWH-
015 (5 μM).  Cell-free supernatants were collected and stored at -70°C until 
analysis. TNF-α and NO levels in the supernatants were examined using ELISA 
kits (R&D Systems) and NO assay (Calbiochem) in strict accordance with the 
manufacturers' protocols.  Cell lysates were also prepared and the Bio-Rad 
protein assay (Hercules, CA) was performed to measure total cellular protein. 
Results are shown as mean pg of TNF-α or NO per mg of total cellular protein 
(+/- SD). 
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4.2.9 JAK/STAT1 signaling pathway analysis 
Primary culture microglial cells were plated in 6-well tissue culture plates 
at a density of 5 × 105 cells per well and co-incubated with IFN-γ (100 U/mL) in 
the presence or absence of a dose range of CB2 agonist (0.31, 0.62, 1.25, 2.5 
and 5.0 μM) for 30 min.  At the end of the treatment period, microglial cells were 
washed in ice-cold PBS three times and lysed in ice-cold lysis buffer.  Total 
protein content was estimated using the Bio-Rad protein assay.  For 
phosphorylation of JAK1 and JAK2, membranes were first hybridized with 
phospho-specific Tyr1022/1023 JAK1 or Tyr1007/1008 JAK2 antibody (Cell 
Signaling Technology, Beverly, MA) and then stripped and finally analyzed by 
total JAK1 or JAK2 antibody.  For STAT1 phosphorylation, membranes were 
probed with a phospho-Ser727 STAT1 antibody (Cell Signaling Technology) and 
stripped with stripping solution and then re-probed with an antibody that 
recognizes total STAT1 (Cell Signaling Technology).  Immunoblotting was 
performed with an anti-rabbit HRP-conjugated IgG secondary antibody as a 
tracer. After washing in TBS the membranes were incubated in luminol reagent 
and exposed to x-ray film. 
 
4.2.10 Microglial Aβ phagocytosis assays 
Microglial phagocytosis of fibrillar/aggregated Aβ1–42 peptide was carried 
out in a manner similar to previously described protocols (Webster et al. 2001, 
and Wyss-Corey et al. 2003).  Microglial cells were cultured at 5 × 105/well in 6-
well tissue-culture plates with glass inserts (for fluorescence microscopy).  The 
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following day, microglial cells were treated with Cy3-conjugated Aβ1–42 (3 μM) 
and CD40L protein (2.5 μg/mL) in the presence or absence of CB2 agonist (5 μM) 
for 3 hr.  Microglial cells were then rinsed 3 times in Aβ1–42-free complete medium 
and the medium was exchanged with fresh Aβ1–42-free complete medium for 10 
min both to allow for removal of nonincorporated Cy3- Aβ1–42 and to promote 
concentration of the Cy3- Aβ1–42 peptide into phagosomes.  This medium was 
withdrawn and microglial cells were rinsed 3 times with ice-cold PBS.   
For fluorescence microscopy, microglial cells on glass coverslips were 
fixed for 10 min at 4°C with 4% (w/v) paraformaldehyde (PFA) diluted in PBS.  
After three successive rinses in TBS, microglial cell nuclei were detected by 
incubation with DAPI for 10 min and finally mounted with fluorescence mounting 
media containing Slow Fade antifading reagent (Molecular Probes, Eugene, OR) 
and then viewed under an Olympus IX71/IX51 fluorescence microscope 
equipped with a digital camera system to allow for digital capture of images 
(40×).   
For immunoblot detection of cell-associated Aβ, primary microglial cells 
were plated in 6-well tissue culture plates with glass inserts at 5 × 105 cells/well 
and treated as described for immunofluorescense detection of Cy3- Aβ1–42 except 
that these experiments employed Aβ1–42.  Immunoblotting was carried out with 
the monoclonal antihuman Aβ antibody (BAM-10, 1:1,000 dilution; Sigma) 
followed by an anti-mouse IgG-HRP as a tracer.  Blots were developed using the 
Immun-Star chemiluminescence substrate.  The membranes were stripped and 
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then reprobed with a reference anti-mouse β-actin monoclonal antibody, which 
allows for quantification of the band density ratio of Aβ to β-actin. 
 
4.2.11 Statistical analysis 
Data are presented as mean +/- SD. All statistics were analyzed using a 
one-way multiple-range analysis of variance test (ANOVA) for multiple 
comparisons. A value of p<0.05 was considered significant.  
 
4.3 Results 
 
4.3.1 Microglial cells express CB2 
In order to examine whether CB2 might be expressed in cultured microglial 
cells, we first isolated total RNA from primary cultured microglial cells for reverse 
transcriptase polymerase chain reaction (RT-PCR) analysis.  Results show that 
CB2 mRNA is constitutively expressed in primary cultured microglial cells (Figure. 
4.1A) and, more importantly, is significantly increased following IFN-γ (50 U/ml 
and 100 U/ml) challenge (Figure. 4.1A, B).  Furthermore, Figure 4.1C and 4.1D, 
show that CB2 protein is detected in primary cultured microglial cells and is also 
markedly increased following the challenge with IFN-γ, by Western blotting.  To 
further evaluate CB2 expression in microglial cells, we performed 
immunohistochemistry on adult mouse brain and found that adult mouse 
microglial cells stained positively for CB2 (Figure. 4.1E top).  To rule out the 
possibility that microglial cells non-specifically bound anti-CB2 antibody, we pre-
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absorbed the goat anti-mouse CB2 antibody with mouse CB2 blocking peptide.  
The CB2 signal is markedly reduced in mouse brain when the blocking peptide is 
used (data not shown). Moreover, immunohistochemical analysis indicated that 
expression of CB2 by microglial cells was co-localized with microglial cell marker 
Iba-1 (Figure. 4.1E bottom).  
 
4.3.2 Stimulation of CB2 inhibits IFN-γ-induced CD40 expression in 
microglial cells  
In previous studies, we and others showed that expression of constitutive levels 
of CD40 on microglial cells can be induced in response to IFN-γ challenge (Tan 
et al. 1999).  To investigate cannabinoid regulation of CD40 expression in 
microglial cells, primary cultured murine microglial cells were treated with IFN-γ 
(100 U/ml) in the presence or absence of THC, CP55940 or JWH-015 for 12 hr 
and the expression of CD40 was analyzed by flow cytometry.  As expected, the 
treatment of cultured microglial cells with THC, CP55940 and JWH-015 
significantly inhibited CD40 expression induced by IFN-γ (Figure 4.2A). 
Treatment with the CB2 agonist, JWH-015, inhibited IFN-γ-induced CD40 
expression in a dose-related manner (Figure. 4.2B). Furthermore, Western 
blotting examination consistently showed that JWH-015 co-treatment mitigates 
the inducible increase in CD40 protein expression in primary cultured microglial 
cells after IFN-γ treatment (Figure. 4.2C, D). Taken together, these findings 
suggest that stimulation of CB2 decreases CD40 expression on primary cultured 
microglial cells. 
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Figure 4.1 A-B 
A, RT-PCR analysis of murine primary cultured microglial cells.  A 239-bp band 
corresponding to CB2 was specifically generated with primers described in the 
Materials and methods section.  B, Graphical representation of RT-PCR band 
density ratio of CB2 expression normalized to β-actin (mean +/- SD) is shown (n 
= 3 for each condition).  ANOVA with posthoc testing revealed significant 
between-group differences (control versus IFN-γ (50 U/mL) and IFN- γ  (50 
U/mL) versus IFN-γ (100 U/mL); p < 0.005).  
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Figure 4.1 C-E 
C, Western immunoblot analysis of murine primary cultured microglial cells using 
specific antibodies targeting CB2 and β -actin proteins.  D, Western blot band 
density is represented as ratio of CB2 to β-actin (mean +/- SD; n = 4 for each 
condition). ANOVA revealed significant between-group differences [Control 
versus IFN-γ (50 U/mL) and IFN-γ (50 U/mL) versus IFN-γ (100 U/mL); ** p < 
0.005].  E, Cannabinoid receptor CB2 is expressed in microglial cells in situ. In 
white matter, microglial cells are positive in their somata and processes for CB2.  
White arrowheads show positive cells as indicated.  The expression of CB2 
(FITC; green) was co-localized with Iba-1, microglial cell marker (TRITC; red) as 
indicated.  Bottom panel denotes merge signals.  Bar denotes 10 μm. 
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4.3.3 Anti-CB2 small interfering RNA blocked effect of CB2 agonist JWH-015 
treatment 
N9 cells transfected for 18 hrs with specific murine CB2 targeting siRNA 
(100 nM) were treated for 4 hr with LPS, JWH-015, or in various combinations, 
and TNF-α release was measured by ELISA (Figure 4.3A).  Anti-CB2 siRNA was 
able to completely abolish JWH-015-mediated reductions in LPS-induced TNF-α 
release.  In addition, to evaluate the knock-down efficiency we performed 
western blot using anti-CB2 antibody and found a significantly decreased level of 
CB2 expression in siRNA transfected condition (Figure 4.3B). These data indicate 
that JWH-015 is activating CB2 to oppose the TNF-α release caused by LPS 
treatment    
 
4.3.4 CB2 agonist inhibited JAK/STAT signaling induced by IFN-γ in 
microglial cells 
Previous reports demonstrate the ability of IFN-γ to potently induce 
microglial CD40 expression (Tan et al. 1999b).  The signal transduction pathway 
involved in this induction most likely involves elements of the JAK/STAT signaling 
pathway (Nguyen and Benveniste. 2000).  Interestingly, many of the factors 
(cytokines, neurotrophins, neuropeptides, and statins) that inhibit IFN-γ-induced 
microglial CD40 expression do so by modification of the JAK/STAT pathway 
(Delgado. 2003).  Therefore, we examined the effects of stimulation of CB2 on 
the JAK/ STAT signaling pathway in primary cultured microglial cells.  Cultured 
microglial cells were treated with IFN-γ for 30 mins in the presence or absence of 
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a dose range of CB2 agonist JWH-015.  Western immunoblotting analysis 
revealed that JWH-015 treatment markedly mitigated JAK1 Tyr1022/1023 and 
JAK2 Tyr1007/1008 phosphorylation in a dose-dependent manner (Figure. 
4.4A,B).  Further, it is well known that during IFN-γ interaction with its 
heterodimer type II cytokine receptor, the JAKs are directly activated leading to 
STAT1 phosphorylation (Delgado 2003).  Accordingly, the effects of CB2 
stimulation on STAT1 phosphorylation, in the same dose range mentioned 
above, on primary microglial cells was examined after treatment with IFN-γ for 30 
mins.  Results showed that JWH-015 co-treatment significantly inhibited Ser727 
phosphorylation of the STAT1 protein at 10 μM (Figure. 4.3C).  Unstimulated 
microglial cells displayed very little detectable JAK1,2 or STAT-1 phosphorylation 
(data not shown). 
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Figure 4.2 C-D 
 
C, Western blot analysis by anti-mouse CD40 antibody shows CD40 protein 
expression and, by anti-β-actin antibody, shows β-actin protein (internal 
reference).  D, Densitometric quantification of Western immunoblotting analysis 
from independent experiments (n = 2 for IFN-γ; n = 3 for IFN-γ/JWH-015 
treatment) indicated that doses of JWH-015 of 1.25 μM or greater significantly (** 
p < 0.05) reduced IFN-γ-induced CD40 expression.  CD40 expression is shown 
normalized to β-actin. 
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Figure 4.3 A-C 
Cultured microglial cells (N9) treated with LPS and 100 nM anti-murine CB2 
siRNA lose their ability to respond to CB2 agonist, JWH-015.  A, Microglial cells 
treated with LPS (100 ng/mL) secreted large quantities of TNF-α (n =3, **p < 
0.005).  Co-treatment with JWH-015 (5 μM) attenuated LPS-induced TNF-α 
release.  Pre-treatment with anti- CB2 siRNA abolished JWH-015's ability to 
reduce LPS-induced TNF-α release (n = 3, ** p < 0.05).  Non-targeting anti-GFP 
siRNA control had no effect.  B and C, Western blot using an anti-murine CB2 
antibody demonstrates that 100 nM anti- CB2 siRNA significantly reduced 
expression of CB2 protein by N9 microglial cells after 48 hr (n = 2, ** p < 0.05). 
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4.3.5 Stimulation of CB2 inhibits functional CD40 signaling in microglial 
cells 
To examine the functional consequences of CB2 agonist treatment on 
CD40 expression, we stimulated mouse primary microglial cells with either IFN-
γ/CD40L protein (Tan et al. 1999a or Aβ1–42/CD40L protein in the presence or 
absence of JWH-015 for 24 hrs.  Supernatants from each treatment condition 
were examined by ELISA for proinflammatory molecules that we have previously 
described as being induced by microglial CD40 ligation (Webster et al. 2001).  As 
we expected, ELISA measurements revealed that either IFN-γ /CD40L or Aβ1–
42/CD40L increased the secretion of the pro-inflammatory molecules TNF-α and 
NO, as indicated in Figure 4.5A and 5B.  However, when CB2 is stimulated by the 
presence of JWH-015, these proinflammatory molecules were significantly 
reduced.  The canonical microglial function in the CNS is thought to be 
phagocytosis, and given that IFN-γ and CD40 signaling are maturation agents 
that oppose this phagocytic function (Monsonego et al. 2003a), we examined 
whether CB2 agonist cotreatment could rescue microglial phagocytic function.  
Murine primary microglial cultures were exposed to 3 μM of Aβ1–42 (for 
immunoblotting) or Cy3- Aβ1–42 (for phagocytosis assay) in the presence or 
absence of CD40L protein or CD40L protein/JWH-015.  After 3 hr, the amount of 
phagocytosed Aβ1–42peptide was determined by both qualitative 
immunofluorescence studies (Figure 4.6A) and with quantitative immunoblotting 
experiments (Figure 4.6B and 4.6C).  As shown in Figure 6A, CD40 ligation  
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Figure 4.5 A-B 
CB2 stimulation attenuates microglial proinflammatory cytokine release. Mouse 
primary microglial cells were seeded in 24-well tissue-culture plates (1×105/well) 
and co-treated with either IFN-γ (100 U/mL)/CD40L protein (2 μg/mL) or Aβ1–42 (1 
μM)/CD40L protein (2 μg/mL) in the presence or absence of cannabinoid 
receptor CB2 agonist (JWH015, 5 μM) for 24 hr.  Cell cultured supernatants were 
collected and subjected to TNF-α cytokine ELISA (A) and NO release assay (B) 
as indicated.  TNF-α production was represented as mean pg of TNF-α per mg of 
total cellular protein (+/- SD).  Similar results were obtained in three independent 
experiments.  ANOVA and post hoc testing revealed significant differences 
between IFN-γ, CD40L, and IFN-γ/CD40L and JWH-015 (** p < 0.005); Aβ1–
42/CD40L, and Aβ1–42/CD40L, plus JWH-015 treatment (** p <0.001). 
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 Figure 4.6 A-C 
CB2 stimulation modulates microglial phagocytic function.  A, Mouse primary 
microglial cells were seeded in 6-well tissue culture plates with glass inserts 
(5×105cells/well) and treated with 3 μM Cy3™- Aβ1–42in the absence (a and b; 
Control) or presence of either CD40L protein (c and d 2.5 μg/mL) or JWH-015 (e 
and f; 5 μM), or both JWH-015 and CD40L protein (g and h).  After 3 hr these 
cells were washed and fixed (see Materials and Methods).  Subsequently, 
immunofluorescence microscopy examination was performed using a 40 X 
objective with appropriate filter selection.  The darkfield images a, c, e, and g 
show the fluorescence of Cy3™ labeled Aβ1–42 whereas, b, d, f, and h show only 
the DAPI nuclear stain of the same fields.  B, In parallel experiments, under the 
same treatment conditions, microglial cell lysates were prepared for Western 
immunoblotting analysis (see Materials and methods) of cell-associated Aβ1–42 
using anti-Aβ antibody (BAM-10, Sigma).  C, Aβ mean band densities are 
graphically represented as ratios to β-actin +/- SD (n = 3 for each condition).  
ANOVA revealed significant betweengroup differences (JWH-015/Aβ versus 
CD40L/Aβ and Aβ/CD40L versus JWH-015/CD40L/Aβ; ** p < 0.005), and post 
hoc testing showed significant differences between CD40L/Aβ and JWH-
015/CD40L/Aβ (** p < 0.005). 
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decreased microglial phagocytic function compared to controls (Figure 4.6A, 
panel a, b versus c, d), while CB2 agonist treatment alone increased compared to 
control (Figure 4.6A, panel a, b versus c, d).  Interestingly, the presence of JWH-
015 rescued microglial phagocytosis of Cy3- Aβ1–42following CD40L treatment 
(Figure. 4.6A, panel g, h versus e, f).  In a parallel experiment, we further showed 
that CB2 stimulation by JWH-015 resulted in a significant attenuation of CD40L-
mediated impairment of microglial phagocytosis of Aβ1–42, as evidenced by 
increased band density ratio of Aβ to β-actin using Western immunoblotting 
(Figure. 4.6B and 4.6C). 
 
4.4 Conclusions 
The findings of the present study suggest that cannabinoids, namely THC 
or the CB2 agonist JWH-015, are effective tools at reducing inflammation through 
stimulation of the CB2 cannabinoid receptor.  The expression of CB2 receptors on 
microglia has been a widely debated issue due to inconsistencies in antibody 
specificity, and low expression levels found in resting cells.  Here the CB2 
receptor is characterized on microglia through reverse transcription PCR and 
western blotting.  The use of anti-CB2 siRNA was also a useful tool to investigate 
the expression of this receptor on microglia.  The resultant knockdown of the 
receptor was further validated functionally by abolishing JWH-015’s ability to 
reduce LPS-induced TNF-α release.   
Administration of JWH-015 to microglia reduces IFN-γ-induced up-
regulation of CD40 expression in mouse microglial cells observed through FACS 
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analysis and further verified by western blotting.  This decrease was not only 
concentration dependent, but resulted in reductions in proinflammatory cytokine 
production induced by CD40L protein.  CD40 expression induced in microglial 
cells by IFN-γ has been shown to be dependant upon signaling through the 
JAK/STAT1 pathway.  Treatment with the CB2 agonist JWH015 inhibits IFN-γ-
induced microglial CD40 expression by opposing JAK/STAT1 pathway activation.  
Selective activation of CB2 receptors was also able to promote microglial uptake 
of Aβ in the presence of CD40 ligation.  These data, suggesting that the CB2 
agonist JWH-015 promotes microglial phagocytic function, are of great interest 
given that mechanisms driving the clearance of cerebral Aβ underlie principles of 
many therapeutic strategies for AD. 
  
 
CHAPTER 5 
 
CO-ADMINISTRATION OF NICOTINE AND ∆9-THC REDUCE 
INFLAMMATION IN VIVO 
 
5.1 Co-administration of Nicotine and ∆9-THC 
Both endogenous cannabinoid and cholinergic systems are crucial 
modulatory pathways in the CNS (Klein et al., 2003, Cobb and Davies 2005), and 
several studies have suggested a possible functional interaction between these 
two systems.  Interestingly, cannabinoid agonists modulate the release and the 
turnover of ACh in various brain areas.  For example, cannabinoid agonists 
cause an elevation of ACh release in hippocampus, cortex and striatum (Mishima 
et al., 2002). 
The specific biochemical consequences of the interaction between THC 
and nicotine are poorly documented in animal models in spite of the high 
frequency of association of these two substances in humans.  Only one early 
study has reported an acute behavioral interaction in rats between compounds 
on locomotor activity, heart rate and body temperature (Felder and Glass, 1998).  
Furthermore, the cataleptic effects induced by THC have been reported to be 
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facilitated by muscarinic, not nicotinic, agonists (Pertwee and Contestabile, 
1999). 
Both nicotine and ∆9-tetrahydrocannabinol (THC) are well known to have 
immune suppressing properties, but no previous studies have investigated their 
combined effects on innate immune system function, despite the fact that most 
marijuana users use both drugs together.  While potentially detrimental during 
development, the ability of both nicotine and THC to suppress immune function 
may be therapeutic in treating chronic pro-inflammatory diseases.  Almost all 
degenerative diseases of the central nervous system are connected to chronic 
inflammation (Orr et al., 2002).  For example, a growing body of evidence 
suggests that innate immunity is pathologically upregulated in various 
neurodegenerative disease states such as Alzheimer's disease (AD) (Nelson et 
al., 2002).  A central step in this process is the activation of microglia, the 
mononuclear phagocyte cells found in the brain (Polazzi, 2002).  Microglia 
represent a major cellular component of the brain, where they constitute a widely 
distributed network of immunoprotective cells.  Activation of microglial cells have 
been proposed to contribute to neuronal dysfunction and neuronal cell death in 
Alzheimer's disease (Munch 2003).  Upon activation, microglia release pro-
inflammatory cytokines, such as TNF-α, which have been implicated in causing 
these effects.  Earlier chapters detailed that α7 nicotinic receptors are functionally 
expressed on microglia and that nicotine reduced microglial activation and 
enhanced microglial phagocytosis of Aβ1-42, a peptide implicated in AD. In 
addition, cannabinoid receptor (CB2) activation similarly reduced microglial 
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activation and enhanced microglial phagocytosis of Aβ1-42 via inhibition of the 
CD40 signaling pathway.  Therefore, it is hypothesized that the combination of 
nicotine and THC will represent a potentially powerful therapeutic strategy 
against pro-inflammatory diseases like AD.  AD is a devastating 
neurodegenerative disease that currently affects an estimated 4.5 million 
Americans, costing the U.S. more than $100 billion annually. Finding a treatment 
that could delay onset by five years could reduce the number of individuals with 
AD by nearly 50 percent after 50 years. This research will also lead to a better 
understanding of how the innate immune system is affected when responding to 
the actions of both nicotine and THC concurrently, something that is occurring 
already in a significant proportion of the population.  
 
5.2 Materials and Methods 
 
5.2.1 Animals 
The previous study by Nordberg (2002) assessed the effects of chronic 
nicotine in transgenic mice expressing a mutant human a chimeric mouse/human 
amyloid precursor protein (APPsw). However, this mouse strain does not show 
plaque deposits until 18 months of age.  For our study, we plan to use a newer 
double transgenic mouse strain expressing both a mutant human presenilin and 
amyloid precursor protein (Jankowsky et al. 2001).  Due to the double mutation, 
this APPsw/PSEN1dE9 transgenic strain (PSAPP) develops brain β-amyloid 
deposits by 8 months of age allowing for more expedient pharmacological 
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testing.  PSAPP mice and their littermates will be generated from the Tan colony 
of PSAPP mice (APPsw, PSEN1dE9) mice.  Housing and maintenance of these 
mice is according to standard practice (accreditation #A4100-01). 
 
5.2.2 Nicotine and ∆9-THC co-treatment 
As stated previously, Nordberg et al., (2002) found that nicotine treatment 
significantly reduced the amount of insoluble Aβ1-40 and Aβ1-42 in APPsw mice 
brains after both short (10 days) and long-term (5.5 months) (hellstrom-Lindahl et 
al. 2004) treatment and from cerebral vessels as well as parenchyma.  The 
reduction in β-amyloid plaque observed in these studies of nicotine treatment 
was comparable to that observed in 16 month APP mice receiving 8.5 months Aβ 
immunization (Morgan et al., 2000).  In Nordberg's study of short-term nicotine 
treatment, 9-month-old Tg2576 transgenic mice were injected subcutaneously 
(s.c.) twice daily for 10 days with either nicotine (Sigma) or saline. The dose of 
nicotine used in that study was 0.45 mg/kg (free base) per day. Because the 
magnitude of the reduction in insoluble Aβ1-40 and Aβ1-42 peptides after 10 days 
of nicotine treatment at this dose was so large (~80%), we will use half the dose 
of nicotine (0.2 mg/kg/day) to avoid having a ceiling effect and missing the 
potential interaction between nicotine and THC. 
Because no previous studies have investigated the effects of THC on AD-
like pathology in AD transgenic mice, we decided to model our dose selection 
based on similar studies of THC effects on innate immune function in mice.  
Recently, Steffens et al., (2005), investigated the effects of 11 weeks 
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administration of THC (0.1 - 10 mg/kg) administration in a well established model 
of atherosclerosis, a chronic inflammatory disease.  They found that 1 mg/kg per 
day resulted in significant inhibition of disease progression as reflected by fewer 
plaque-infiltrating macrophages and decreased capacity of lymphoid proliferation 
and INF-γ secretion.  Therefore, a similar, but narrower dose range (0.3-3 
mg/kg/day) was used.  The treatment duration consisted of once daily i.p. 
injections lasting for a 2 month period, after which animals were sacrificed and 
tissues collected. 
Studies looking into whether nicotine/THC administration to PSAPP mice 
will result in reduced cytokine production, and AD-like pathology (including 
amyloidosis and microglia associated inflammation) were perfomed.  
Administration of nicotine/THC to 12 month of PSAPP mice, after the 
development of AD-like pathology (therapeutic treatment) was employed to 
investigate these effects.  Each treatment group comprised 8 mice, 4 males and 
4 females.  Following 2 month of therapeutic treatment with nicotine/THC, the 
mice were sacrificed and blood withdrawn. Mice were transcardially perfused 
with saline and the brain bisected sagitally with the left half immersion fixed in 
paraformaldehyde for histological processing and the right half processed for 
biochemical testing. 
Aβ deposition will be measured both histologically with Aβ 
immunohistochemistry and Congo red staining and biochemically by ELISA for 
total Aβ1-40/Aβ1-42.  We will evaluate CD45, a microglial marker of activation, and 
GFAP, an astrocyte activation marker to asses the overall activation state.  We 
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will also examine the cytokines IL-6, and TNF-α in brain tissue to evaluate the 
degree to which inflammation is occurring in the brain. 
 
5.3 Results 
 
5.3.1 In vitro analysis of nicotine and ∆9-THC co-administration 
 To test the effect of nicotine and THC co-administration in vitro, murine 
primary microglial cells were cultured as previously decribed (Tan et al. 2000b).  
Cultures were plated in 24 well tissue culture plates at 1x105 cells per well.  The 
cells were then pretreated for 30 min with varying concentrations of nicotine 
(0.625-10μM), THC (0.625-10μM), or their combination.  After pretreatment, cells 
were challenged with LPS (100ng/ml) for 4 hours.  TNF-alpha and IL-6 release 
was measured in cell-free supernatants by ELISA, and results were normalized 
to total protein levels.  Co-administration of nicotine and THC was more effective 
at reducing TNF- alpha (Fig 5.1a) and IL-6 (Fig 5.1b) secretion from microglia 
than either compound alone.   
 
5.3.2 In vivo validation of nicotine and ∆9-THC co-administration 
 Since the co-administration of nicotine and THC has not been investigated 
previously in vivo, non-transgenic C57BL/6 mice were used to validate the dosing 
regimen.  Varying, physiologically relevant concentrations of nicotine (0.25-
1mg/kg), THC (0.3-3mg/kg), and their combination were injected intraperitoneally 
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Figure 5.1 
 
Combination of nicotine and ∆9-THC is more effective at reducing cytokine 
production from microglia than either compound alone.  Mouse primary culture 
microglial cells were cultured in 24 well tissue-culture plates (1x105) and treated 
with varying concentrations of nicotine, THC, or their combination for 30 min.  
The cells were then challenged with LPS for 4 h.  TNF-alpha (5.1a) and IL-6 
(5.1b) were assayed by ELISA kit, and results were normalized to total protein 
per well. 
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 (n=10/group).  Immediately following this injection, the bacterial endotoxin 
lipopolysaccharide (LPS) (1mg/kg) was injected intraperitoneally to challenge the 
animals and promote an inflammatory condition and cytokine production.  The 
mice were sacrificed 4hrs later, and brains were collected for biochemical 
analysis.  Animals receiving both compounds showed a significant decrease in 
TNF-α production when compared to LPS alone (fig 5.2).  Co- administration of 
nicotine and THC also resulted in a greater reduction than either compound 
alone.   
 There is not much data detailing acceptable doses for THC, when looking 
for anti-inflammatory effects in the brain.  While extensive literature is present 
investigating this phenomenon with nicotine (Conejero-Goldberg et al. 2003) (de 
Jonge and Ulloa. 2007).  Therefore an additional experiment using non-
transgenic mice was designed where the concentration of nicotine remained 
constant at 0.25 mg/kg and the dose of THC (0.03-0.3 mg/kg) was reduced from 
earlier experiments to determine the lowest effective dose (fig 5.3).  This will 
allow for maximum therapeutic benefit, while limiting psychoactive effects.  
Animals were intraperitoneally injected (n=10/group) with a combination of  
nicotine and varying concentrations of THC, followed by LPS (1mg/kg).  After 4 
hrs, brains were collected, homogenized, and assayed for TNF-α using ELISA.  
Results show that a dose of nicotine at 0.25 mg/kg, along with THC at 03 mg/kg, 
in these animals, was most effective at reducing TNF-α production stimulated by 
LPS.   
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Figure 5.2 
Reductions in TNF-α after administration of nicotine and ∆9-THC in non-
transgenic mice.  Since the combination of nicotine and ∆9-THC has not been 
investigated previously in vivo, an inflammatory model using LPS in non-
transgenic mice was employed to look at the effects of these compounds on 
TNF-alpha production.  Non-transgenic C57BL/6 mice were injected 
intraperitoneally with varying concentrations of nicotine (0.25-1 mg/kg), THC (0.3-
3mg/kg) and one dose combined (0.25 & 0.3 mg/kg respectively).  Mice were 
challenged with LPS (i.p., 1mg/kg) and sacrificed 4h after injection.  TNF-alpha 
from brain homogenate was assayed by ELISA.  Data normalized to total protein.  
(n=10 (5 female/5 male) at 6 months of age (single dose/LPS/i.p., 1 mg/kg) 
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Figure 5.3 
Reductions in TNF-α after administration of nicotine and ∆9-THC in non-
transgenic mice.  To further refine in vivo dosing of nicotine and THC, non-
transgenic mice were injected with lower doses of THC (0.03-03 mg/kg) while the 
dose of nicotine remained constant (0.25 mg/kg).  Mice were challenged with 
LPS (i.p., 1mg/kg) and sacrificed 4h after injection.  Animals were perfused, 
brains isolated, and TNF-alpha from brain homogenate was assayed by ELISA.  
(n = 10 (5 female/5 male) at 6 months of age (single dose/LPS/i.p., 1 mg/kg) 
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5.3.3 Nicotine and ∆9-THC reduce pro-inflammatory cytokine production 
and Aβ pathology in PSAPP transgenic mice 
 To test the effects of nicotine and THC co-administration on a case of 
neuroinflammation that does not require an exogenous stimuli, such as LPS, a 
transgenic alzheimer mouse model expressing the swedish mutation of APP 
(APPsw), and a presenillin 1 mutation (PSEN1dE9) was used.  These mice, 
labeled PSAPP, show accelerated alzheimer pathology with Aβ plagues forming 
at approximately 8 months of age.  Based on the previous work in non-transgenic 
animals, one concentration each of nicotine (0.25 mg/kg) and THC (0.3 mg/kg) 
was chosen for administration to PSAPP mice (n=8/group).  Animals were 
intraperitoneally injected once daily with either nicotine, THC, or the combination 
of the two compounds together for 2 months.  At the end of the treatment period, 
the PSAPP mice were sacrificed, transcardially perfused, and brains collected for 
biochemical and histological examination.   
 The right hemisphere was homogenized in ice cold lysis buffer with a 
protease inhibitor cocktail to prevent protein degradation.  PSAPP brain 
homogenates were analyzed for pro-inflammatory cytokines by ELISA.  Neither 
nicotine nor THC alone reduced TNF-alpha expression compared to controls 
(PBS - fig 5.4).  While co-administration of the drugs resulted in a significant 
decrease in TNF-alpha production when compared to PBS alone.  This same 
trend is observed in the results of the IL-6 ELISA.  The combination of nicotine 
and THC significantly reduced IL-6 expression in the PSAPP mouse model 
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Figure 5.4 
Nicotine and ∆9-THC reduce cytokine production in 12 month old PSAPP 
Alzheimer transgenic mice.  Animals were injected once daily with nicotine (0.25 
mg/kg), THC (03 mg/kg) or the both compounds combined for two months.  The 
cytokines TNF-α and IL-6 were detected, using ELISA, from brain homogenates.  
Cytokine production is represented as mean pg of TNF-α or IL-6 per mg of total 
protein (+/- SD).   
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 To investigate the possible effects of nicotine and THC on the Aβ 
pathology produced in the PSAPP mice.  Brain homogenates were tested by Aβ 
ELISA for total soluble, and total insoluble (from 5M guanidine extraction) Aβ1-40, 
42.  Again, the combination of nicotine and THC had a greater effect then either 
drug administered alone.  Reductions in total soluble Aβ in the nicotine/THC 
treated group was found to be significant when compared to control PBS 
animals, while reductions in insoluble levels were not.  These reductions in Aβ 
pathology were further supported by IHC staining of Aβ using the anti- Aβ (1-16) 
6E10 antibody (fig 5.6a).  Images here show that nicotine/THC treated groups 
show a decrease in diffuse amyloid pathology while most insoluble plagues 
remain.  Congo red staining (fig 5.6b) also verified observations found of 
insoluble plaque pathology, showing no significant change in positive staining.  
Image analysis of 6E10 and congo red staining was performed using Image J 
(NIH) software to calculate the percent of Aβ burden (fig 5.6c) 
 Histologic analysis of cell specific activation markers was performed on 
nicotine and THC treated PSAPP animals.  Selected sections were stained using 
antibodies to CD45, to identify activated microglia, GFAP for activated 
astrocytes, the anti- Aβ antibody 6E10.  Image analysis (Fig 5.7c) was performed 
using ImageJ (NIH) software to calculate the percent of positive CD45 (Fig 5.7a) 
and GFAP (Fig 5.7b) staining per total area.  Analysis shows overall a 50% 
reduction in positive CD45 microglial staining in groups given nicotine/THC, 
compared to PBS controls.  Concurrently, reductions in GFAP staining were also 
observed in PSAPP animals receiving nicotine/THC co-administration.   
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Figure 5.5 
Nicotine and ∆9-THC reduce amyloid load in 12 month old PSAPP Alzheimer 
transgenic mice.  Animals were injected once daily with nicotine (0.25 mg/kg), 
THC (0.3 mg/kg) or the both compounds combined for two months.  Soluble and 
insoluble Aβ fractions were isolated from brain homogenates, and detected using 
ELISA.  The combination of nicotine and THC significantly (**p < 0.05) reduced 
total soluble Aβ over PBS controls.  Results are represented as mean pg of 
soluble or insoluble Aβ per mg of total protein (+/- SD). 
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Figure 5.6c 
 
Nicotine and ∆9-THC reduce amyloid load in 12 month old PSAPP Alzheimer 
transgenic mice.  Animals were injected once daily with nicotine (0.25 mg/kg), 
THC (03 mg/kg) or the both compounds combined for two months.  6E10 staining 
of total Aβ is seen in fig 5.6a, Congo red staining of mature plaques is seen in Fig 
5.6b.  Top panels are from dentate gyrus (DG), middle panels are from 
hippocampal CA3 or CA1 regions, and bottom panels are from the entorhinal 
cortex (EC).   
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Figure 5.7c 
 
Intraperitoneal injection of nicotine and ∆9-THC reduce inflammatory markers in 
PSAPP mice.  Mouse brain coronal sections were stained with rabbit polyclonal 
anti-human Aβ antibody (cy3), and CD45 activated microglial marker (5.6a) or 
activated astrocytic marker GFAP (5.6b) (FITC).  Sections were wet mounted 
with DAPI to show cell nucleus, and images using confocal microscopy were 
obtained.  Top panels: control PSAPP mice. Bottom panels: PSAPP mice treated 
with nicotine and THC, respectively.  Percentage of positive CD45 (5.6a) and 
GFAP (5.6b) staining (mean + SD) were quantified with image analysis (5.6c).  A 
t test for independent samples revealed significant differences (n = 8 for each 
condition; *p<0.05; **p<0.001) 
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5.4 Conclusions 
 The studies detailed in this chapter show that the co-administration of 
nicotine and THC together are more effective at reducing inflammation than 
either drug alone.  This finding is first observed in vitro, using primary culture 
mouse microglial cells.  Co-administration of these two compounds reduced pro-
inflammatory cytokine production observed through TNF-α and IL-6 ELISA assay 
of culture media.  Later studies show that this co-administration is also effective 
at reducing the inflammation in both acute (LPS) and chronic (PSAPP) cases of 
neuroinflammation.  Treatment with both compounds reduced pro-inflammatory 
cytokine production observed in both models.  In accordance with this, the co-
administration of nicotine and THC reduced both CD45 staining active microglia, 
and GFAP reactive astrocytes seen in PSAPP transgenic animals.  Investigations 
into the Aβ pathology, observed by ELISA and tissue staining, in the PSAPP 
mice showed reductions in Aβ levels, and Aβ positive staining in tissue sections.  
Taken together, these data suggest that co-activation of both the α7 nAChR and 
the cannabinoid CB2 receptor may be a viable therapeutic approach for reducing 
neuroinflammation in chronic cases of neurodegenerative disease.   
  
 
CHAPTER 6 
 
DISCUSSION 
 
 Although past ideologies classify the CNS as immune-privileged, innate 
and adaptive immune responses can occur in the CNS and allow for protection 
from infectious agents and clearance of debris.  These innate and adaptive 
immune responses also allow for the stimulation of tissue repair within the CNS.  
Due to these roles, immune responses in the CNS should be regarded as 
primarily beneficial.  Chronic activation of these immune responses can 
ultimately lead to problems, and is a hallmark on many neurodegenerative 
diseases.  For example, in AD, Aβ has been shown to cause pro-inflammatory 
cytokine production and reactive oxygen species (ROS) generation through 
activation of microglial cells (Nelson et al., 2002).  This chronic inflammatory 
state can eventually lead to neuronal cell death and cognitive dysfunction.  The 
processes that cause and drive this chronic activation are not fully understood, 
and most likely have different stimuli based on the neurodegenerative disease in 
question.   
Activated microglia are a common feature in many neurodegenerative 
disorders, and are considered one of the driving forces in producing the chronic 
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inflammation observed.  They have been shown to have a neurotoxic (M1) or 
neuroprotective (M2) phenotype, depending on the type and extent of stimuli they 
receive.  It has also been argued that microglia may make a transition from 
neuroprotective to neurotoxic based on the size and duration of the neuronal 
insult.  Studies in transgenic mouse models of AD have shown an age-
dependent shift from the protective M2 to the inflammatory M1 phenotype as Aβ 
pathology in these animals accumulates (Jimenez et al., 2008).  Also after CNS 
injury in normal mice, microglia initially show a transient/acute inflammatory M2 
response that was quickly overtaken by the M1 neurotoxic response, indicating 
that this phenomenon may be common in other neurodegenerative disorders as 
well (Kigerl et al., 2009).  Two subtypes of receptors, the α7 nAChR and the 
cannabinoid receptor CB2, may have the ability to reset the M1/M2 balance by 
reducing pro-inflammatory cytokine production and allowing for tissue 
reconstruction and repair (Conerjero et al., 2008, Fernandez-Ruiz et al., 2008).   
 
6.1 Microglia express functional α7 nAChRs 
Findings here demonstrate that physiologically relevant concentrations of 
ACh and nicotine (Ghosheh et al. 2001) have the ability to modulate microglial 
TNF-α release evoked by LPS through activation of α7 nAChR.  The report of 
functional α7 nAChR subunit on microglia involves a previously unknown 
cholinergic pathway which can be used to regulate microglial activation.  In the 
peripheral nervous system, a non-neuronal cholinergic system is strongly 
expressed within different components of the immune system and appears to be 
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involved in the regulation of host defense mechanisms and inflammation.  For 
example, it has been shown that efferent vagus nerve stimulation attenuates the 
systemic inflammatory response to LPS in blood-borne macrophages and this 
effect is mediated by the principle vagal neurotransmitter ACh acting at α7 
nAChR (Wang et al. 2003).  While these findings provide evidence for a similar 
role for ACh in regulation of inflammation in the brain, the source of ACh for 
microglial regulation remains unclear.  It has been shown that microglia can carry 
out both neurotrophic and neurotoxic functions in the brain and factors that 
determine which function microglia serve depend on an integration of signals 
received from neighboring astrocytes and neurons (Polazzi and Contestabile 
2002).  These findings, suggest that signals related to the suppression of 
immunological properties of microglia by neurons in the healthy brain and the 
disruption from this physiological equilibrium in aging and diseases, may involve 
neuronal cholinergic communication via α7 receptors. Such an interpretation is 
consistent with the observation that cholinergic neurons decrease with age (Terry 
and Buccafusco 2003) in parallel with increased microglial activation (Streit and 
Sparks 1997).  Moreover, cholinergic neurons are particularly susceptible to the 
neurodegenerative consequences of excessive microglial activation (Wenk et al. 
2000).  Because astrocytes synthesize ACh (Wessler et al. 1997) as well as the 
potent α7 nAChR antagonist kynurenic acid (Hilmas et al. 2001), astrocytes may 
also regulate microglial phagocytosis via a cholinergic signal.  With this in mind, it 
is possible that the loss of cholinergic communication from damaged neurons 
and/or astrocytes may be partially responsible for the turning of microglia to a 
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hyper-activated state, which allows them to escape neuronal control and to give 
rise to chronic inflammation, resulting in exacerbation of neurodegeneration. 
 
6.2 Effects of CB2 stimulation on microglial activation 
The results of the present study suggest that cannabinoids, namely THC 
or the CB2 agonist JWH-015, reduce IFN-γ- induced up-regulation of CD40 
expression in mouse microglial cells by interfering with the JAK/STAT1 pathway.  
Given that this finding is consistent with the immunosuppressive effects of 
cannabinoids reported previously (Berdyshev 2000), the significance of our 
present findings must be considered in the context of the function of microglial 
CD40.  Increased expression of CD40 by microglial cells, in conjunction with the 
release of TNF-α, is directly correlated with pathogenic events occurring in the 
CNS of MS patients (Wagner et al. 2002) and in the EAE mouse model of MS 
(Becher et al. 2001).  In AD, activated microglial cells are considered a major 
contributor to the local inflammatory responses evidenced in neuritic plaques.  
Furthermore, the CD40- CD40L dyad is potentiated, as can be seen from the 
increased numbers of CD40-positive microglial cells as well as increased CD40L 
expression on astrocytes in AD (Togo et al. 2000).  Previous work has shown a 
correlation between increased levels of Aβ peptide and enhanced CD40 
expression on microglial cells derived from the Tg2576 mouse model of AD (Tan 
et al. 1999).  A review of the molecular basis of CD40 expression in 
macrophages/microglial cells illuminates the critical role of the JAK/STAT1 
pathway (Benveniste et al. 2004).  In this study, the CB2 agonist JWH015 inhibits 
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IFN-γ-induced microglial CD40 expression by opposing JAK/STAT1 pathway 
activation.  One possible mechanism of JWH015's inhibition of the JAK/STAT1 
pathway is provided by a recent report showing that treatment with novel 
cannabinoid, PRS-211,092, significantly decreased Concanavalin A-induced liver 
injury in mice that was accompanied by an induction of early gene expression of 
the suppressors of cytokine signaling (SOCS-1 and 3).  The SOCS proteins act 
as negative regulators of the JAK/STAT1 pathway either by binding and inhibiting 
JAK tyrosine kinases or by inhibiting binding of STAT1 factors to the cytoplasmic 
domains of the receptors (Yasukawa et al. 2000).  Results in chapter 4 also show 
that CB2 agonist JWH-015 similarly inhibits microglial CD40 ligation induced 
production of proinflammatory cytokines.  This finding is consistent with studies 
showing that CB2 agonists inhibit microglial production of proinflammatory 
mediators (Ramirez et al. 2005).  These data, suggesting that the CB2 agonist 
JWH-015 promotes microglial phagocytic function, are of great interest given that 
mechanisms driving the clearance of cerebral Aβ underlie principles of many 
therapeutic strategies for AD. 
 
6.3 Co-stimulation of α7 and CB2 receptors in vivo 
 Although previous reports have substantiated the anti-inflammatory 
potential of α7 nAChR and CB2 receptor activation (Lloyd and Williams 2000, 
Buckley et al., 2000, Steffens et al., 2005), there have been no studies looking 
into the combined effects of these receptors together.  The studies detailed in 
chapter 5 show that nicotine and ∆9-THC, when used together, were able to 
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reduce pro-inflammatory cytokine production both in vitro (fig 5.2) and in vivo (fig 
5.3).  The observed reductions in cytokines were greater when the two 
compounds were administered together, rather than either compound alone.  
This observation may be explained simply by the actions of the receptor types 
involved.  The rapid activation of the ligand-gated α7 nAChRs coupled to the 
slower, but longer acting, CB2 GPCRs may allow for a longer therapeutic effect 
and greater reductions in cytokine production (Howlett 2002).  Additionally, this 
increased effect may be due to the separate signaling cascades that these 
receptors have shown to alter in chapters 3 and 4.  The α7 receptor showed 
reduced pro-inflammatory cytokine production by interfering in the MAPK 
signaling pathway (fig 3.4), while CB2 receptors reduced JAK/STAT 
phosphorylation (fig4.4).   
 Deposition of the Aβ protein is one of the major pathological hallmarks of 
AD.  Aβ can be found as both soluble oligomers, and insoluble fibrillar 
(aggregate) plaques within the brain.  Recent studies have implicated the 
oligomeric forms of Aβ as being the predominant toxic species in AD (Deshpande 
et al., 2006).  Fibrillar forms are still considered toxic, but some feel they are 
more of a processing endpoint for the oligomeric forms, rather than the primary 
source of neurodegeneration.  Reductions in Aβ pathology have been shown to 
be beneficial in animal models of AD.  Also, studies have shown that stimulation 
of either α7 nAChRs (Kihara and Shimohana, 2004) or CB2 receptors (Tolon et 
al., 2009) can result in clearance of Aβ pathology.  This observation is further 
supported by ELISA and immunohistochemical data detailed in chapter 5.  
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Significant reductions in total soluble Aβ1-40,42 were observed from PSAPP mice 
treated with nicotine and THC, while small decreases in total insoluble Aβ1-40,42 
were measured (fig 5.5)  Tissue sections stained with 6E10 anti-Aβ antibody and 
congo red also substantiate the claim that co-treatment with nicotine and ∆9-THC 
was able effectively reduce soluble Aβ1-40,42  while only slightly changing 
insoluble levels (fig 5.6).   
 Expression of CD45 on microglia has proven to be a valuable tool in 
determining the inflammatory state of the brain.  Studies have shown an increase 
in CD45 expression in several disease states, including AD (Ho et al., 2005), MS 
(Olson 2010) and HIV dementia (Cosenza-Nashat et al., 2006).  Glial fibrillary 
acidic protein (GFAP) is another well know marker of activation for a different 
glial cell-type known as astrocytes.  Also, similar to CD45, GFAP expression is 
markedly increased in situations of neuroinflammation.  Reductions in either of 
these inflammatory markers have been associated with decreased inflammatory 
stimuli in the brain.  PSAPP mice treated with nicotine and THC showed reduced 
microglial CD45 (fig 5.7a) and astrocytic GFAP (fig 5.7b) expression when 
compared to non-treated transgenic controls.  This was verified through image 
analysis by looking at the percent area of positive stain.  Analysis showed 
significant reductions in both CD45 and GFAP expression by glial cells (fig5.7c). 
 Nicotine, the active ingredient in tobacco, and ∆9-THC, the active 
ingredient in marijuana, are both shown to have immunosuppressive properties.  
Also, the endogenous cholinergic and cannabinoid systems are crucial 
modulatory pathways in the CNS.  Co-stimulation of α7 and CB2 receptors can 
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provide a much needed therapeutic tool in combating chronic inflammation 
observed in neurodegenerative disorders.  Future studies employing currently 
available receptor specific agonists would be extremely helpful in further 
examining the roles of these receptors on microglia, and their effects on other 
animal models of neurodegeneration and CNS inflammation.   
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